https://trial.medpath.com/news/a97f7f5bdc381cdf/first-clinical-trial-of-memory-like-natural-killer-cells-in-ovarian-cancer-opens-at-dana-farber 2024-11-15T15:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/86a8ca975f83e009/fda-approves-azurity-pharmaceuticals-danziten-for-cml-treatment 2024-11-15T15:33:15+00:00 weekly 0.7 https://trial.medpath.com/news/1406fcad682fb234/chmp-recommends-rybrevant-r-amivantamab-in-combination-globenewswire 2024-11-15T15:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/3c182768defdd280/effect-of-ultrasound-guided-individualized-positive-end-expiratory-pressure-on-the-severity-of 2024-11-15T15:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/a8a0a1d96fe9c425/how-to-accelerate-glycolysis-and-treat-parkinson-s-disease-drug-discovery-news 2024-11-15T15:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/0443243b993b8092/delandistrogene-moxeparvovec-fails-to-meet-primary-endpoint-in-phase-3-study 2024-11-15T15:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/a9d480788533117c/application-for-rtw-biotech-opportunities-corxel-s-aficamten-accepted-by-chinese-regulator 2024-11-15T15:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/39bf390910fcb1c7/os-therapies-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-15T15:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/ef210b38f28c3305/fda-approves-ind-for-as1986ns-a-new-approach-in-prostate-cancer-research 2024-11-15T15:05:02+00:00 weekly 0.7 https://trial.medpath.com/news/1ce431f52871196e/foresee-pharmaceuticals-receives-the-second-positive-recommendation-from-dsmb-to 2024-11-15T15:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/8d29e5567b375aec/drug-combination-boosts-immune-response-in-resistant-pancreatic-cancers 2024-11-15T15:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/cc6cc2dd3b74b9fe/fda-sets-date-for-resubmitted-dupixent-in-inflammatory-skin-disease-formulary-watch 2024-11-15T15:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/cc89b426d2a9453c/levicept-presents-positive-phase-ii-data-for-novel-neurotrophin-3-inhibitor-levi-04-for 2024-11-15T14:56:53+00:00 weekly 0.7 https://trial.medpath.com/news/e14dcbfd567a3a5c/t-dxd-sequencing-and-treatment-options-in-the-tumor-agnostic-setting-cancer-network 2024-11-15T14:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/ab0903b59d3a0174/os-therapies-completes-phase-2b-trial-dosing-awaits-key-december-data-ostx-stock-news 2024-11-15T14:54:09+00:00 weekly 0.7 https://trial.medpath.com/news/b56be614a8ac378c/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-15T14:54:08+00:00 weekly 0.7 https://trial.medpath.com/news/9ace2b7a1e283e96/addition-of-veliparib-to-temozolomide-in-newly-diagnosed-mgmt-methylated-glioblastoma 2024-11-15T14:45:06+00:00 weekly 0.7 https://trial.medpath.com/news/9797f2c699a46d3d/new-drug-strategy-reverses-resistance-to-immunotherapy-in-pancreatic-cancer 2024-11-15T14:39:42+00:00 weekly 0.7 https://trial.medpath.com/news/b8d55b2c3c8e10f4/exact-sciences-showcases-early-cancer-detection-test-data-at-aacr-meeting 2024-11-15T14:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/386c4a160407ddfa/scilex-holding-company-announces-presentation-of-data-at-the-2024-american-college-of 2024-11-15T14:24:26+00:00 weekly 0.7 https://trial.medpath.com/news/7490b42cc7331bfa/scilex-s-gloperba-r-showcases-breakthrough-kidney-disease-dosing-data-at-acr-conference 2024-11-15T14:15:32+00:00 weekly 0.7 https://trial.medpath.com/news/731ce850ad426328/cero-therapeutics-secures-fda-clearance-for-novel-aml-treatment-clinical-trial 2024-11-15T14:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/dc4311ace3b2f4a3/rwanda-steps-up-measures-against-rift-valley-fever-gavi-the-vaccine-alliance 2024-11-15T14:08:51+00:00 weekly 0.7 https://trial.medpath.com/news/a3fc14366881eb45/breakthrough-research-promises-shorter-treatment-for-multi-drug-resistant-tb 2024-11-15T13:56:36+00:00 weekly 0.7 https://trial.medpath.com/news/e89e4299c07e9714/fda-decision-on-abeona-s-pz-cel-for-rdeb-now-expected-by-april-29 2024-11-15T13:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/88296cc933a70e52/allogene-halts-enrollment-in-leukemia-trial-by-investing-com 2024-11-15T13:54:39+00:00 weekly 0.7 https://trial.medpath.com/news/f408493abda6db35/samsung-bioepis-receives-positive-chmp-opinion-for-globenewswire 2024-11-15T13:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/3e7ac2b7fe4cecf9/cero-therapeutics-inc-receives-fda-clearance-of-globenewswire 2024-11-15T13:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/959540f0c43f7cf7/fda-approves-kebilidi-first-brain-delivered-gene-therapy-for-rare-aadc-disease 2024-11-15T13:44:35+00:00 weekly 0.7 https://trial.medpath.com/news/7cb8d3d5c67ebbc3/inflarx-gets-ema-nod-for-covid-19-treatment-tipranks-com 2024-11-15T13:38:18+00:00 weekly 0.7 https://trial.medpath.com/news/a79805f9bd5105bb/sbrt-is-feasible-for-localized-prostate-cancer-oncology-nursing-news 2024-11-15T13:38:06+00:00 weekly 0.7 https://trial.medpath.com/news/d6d0d595c6b51855/pds-biotechnology-corporation-nasdaq-pdsb-q3-2024-earnings-call-transcript 2024-11-15T13:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/5585ea8716336061/nanoviricides-pushes-nv-387-to-phase-ii-trials-nyse-a-nnvc-proactive-investors 2024-11-15T13:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/22c3a0cce38cebf4/mixed-reactions-follow-rfk-jr-s-nomination-as-hhs-secretary-raising-public-health-concerns 2024-11-15T13:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/e6e40fc3a11a4e71/from-the-bench-fall-2024-massachusetts-general-hospital 2024-11-15T13:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/8322ac9e5a6fb584/selenium-proteins-breakthrough-in-cancer-research-mirage-news 2024-11-15T13:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/0aa679d8c99ee862/inflarx-receives-positive-chmp-opinion-for-gohibic-r-vilobelimab-for-the-treatment-of 2024-11-15T13:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/3b655b5613a8dc54/genomadix-inc-enters-into-collaboration-with-mayo-clinic-on-precision-medicine-for-telestroke 2024-11-15T13:05:59+00:00 weekly 0.7 https://trial.medpath.com/news/bc6982b39e768e8e/inflarx-s-gohibic-gets-ema-panel-nod-for-covid-19-ards-by-investing-com 2024-11-15T12:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/c0db98e93f0e0b67/inflarx-receives-positive-chmp-opinion-for-gohibic-r-globenewswire 2024-11-15T12:56:02+00:00 weekly 0.7 https://trial.medpath.com/news/c28b2392982f86bb/leveraging-genetic-variations-for-more-effective-cancer-therapies-news-medical 2024-11-15T12:53:20+00:00 weekly 0.7 https://trial.medpath.com/news/04100c6c67ff2ab8/inflarx-receives-positive-chmp-opinion-for-gohibic-r-vilobelimab-for-the-treatment-of 2024-11-15T12:52:23+00:00 weekly 0.7 https://trial.medpath.com/news/d13a93b5d4c8596a/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-11-14 2024-11-15T12:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/c94cdc232305fa83/triglyceride-lowering-therapies-in-hypertriglyceridemia-associated-acute-pancreatitis-in-china 2024-11-15T12:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/67942761045c682a/shingles-vaccination-shows-dual-benefit-virus-prevention-and-cardiovascular-protection 2024-11-15T12:17:23+00:00 weekly 0.7 https://trial.medpath.com/news/2b7a8184bd649a6b/eyenovia-provides-update-on-phase-3-chaperone-study-stock-titan 2024-11-15T12:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/18dd0d5b5b656887/eyenovia-provides-update-on-phase-3-chaperone-study-globenewswire 2024-11-15T12:08:40+00:00 weekly 0.7 https://trial.medpath.com/news/3b71c64a6bb64bae/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-15T12:06:44+00:00 weekly 0.7 https://trial.medpath.com/news/6eb6d52c0c2b08fd/dupixent-r-dupilumab-sbla-accepted-for-fda-review-for-the-globenewswire 2024-11-15T12:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/dce18957f1c37640/j-j-s-nipocalimab-shows-promise-in-phase-ii-sjogren-s-disease-trial-clinical-trials-arena 2024-11-15T11:59:26+00:00 weekly 0.7 https://trial.medpath.com/news/992c3a5ed04081e9/immutep-reports-promising-phase-ii-sarcoma-trial-results-tipranks-com 2024-11-15T11:56:57+00:00 weekly 0.7 https://trial.medpath.com/news/d54e5997ae77dd4f/nanoviricides-antiviral-drug-nv-387-advances-to-phase-ii-trials-amid-funding-needs 2024-11-15T11:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/3ec6a107a570d589/nanoviricides-advances-nv-387-to-phase-ii-trials-for-multiple-viral-infections 2024-11-15T11:45:37+00:00 weekly 0.7 https://trial.medpath.com/news/37f56d116de69887/fda-to-review-sanofi-regeneron-s-dupixent-sbla-for-csu 2024-11-15T11:40:58+00:00 weekly 0.7 https://trial.medpath.com/news/0540bcac0bdc68c3/more-evidence-that-glp-1-meds-curb-alcohol-abuse 2024-11-15T11:03:32+00:00 weekly 0.7 https://trial.medpath.com/news/023b4d228c330bf2/chlamydia-vaccine-shows-early-promise-in-mice 2024-11-15T11:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/6b9cf8e073e055b0/mymelanoma-study-selected-to-join-new-nhs-digitrials-initiative-oxford-cancer 2024-11-15T10:46:01+00:00 weekly 0.7 https://trial.medpath.com/news/1696e07007b59fa6/could-weight-loss-drugs-fix-uk-s-unemployment-problem-al-jazeera 2024-11-15T10:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/32c49f31cc52503c/combination-treatment-for-esophageal-cancer-the-aacr 2024-11-15T10:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/6997fa1b7578d040/blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for 2024-11-15T10:22:01+00:00 weekly 0.7 https://trial.medpath.com/news/06ff2ec516a8c2b7/gsk-reports-positive-outcomes-from-phase-iii-multiple-myeloma-treatment-trial 2024-11-15T10:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/9246b876748c4360/rtw-biotech-notes-drug-approval-in-china-for-investee-corxel-marketscreener 2024-11-15T10:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/2e8d567675ed3be7/improvements-to-children-s-surgery-to-be-identified-with-the-help-of-a-new-nhs-digitrials 2024-11-15T10:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/340696006150d9ba/gene-therapy-discovery-enables-use-for-muscular-dystrophies-and-large-gene-diseases 2024-11-15T10:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/0eafe738c5970023/finally-therapeutic-antibodies-start-to-reduce-tangles-alzforum 2024-11-15T09:52:10+00:00 weekly 0.7 https://trial.medpath.com/news/224badda193e504d/caamtech-s-psychedelic-functional-unblinding-strategy-gets-regulatory-blessing 2024-11-15T09:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/153e21c0157a7e22/ema-s-chmp-recommends-sanofi-s-sarclisa-approval-for-multiple-myeloma 2024-11-15T09:23:26+00:00 weekly 0.7 https://trial.medpath.com/news/266c052e90bd4662/adding-immunotherapy-to-neoadjuvant-chemoradiation-may-improve-outcomes-in 2024-11-15T09:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/c46100492740b123/q1-interim-report-july-2024-september-2024-hamlet-biopharma-ab-publ 2024-11-15T08:48:20+00:00 weekly 0.7 https://trial.medpath.com/news/5e21cd314b78c81e/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-15T08:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/0322f89c17ca4b11/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-15T08:43:36+00:00 weekly 0.7 https://trial.medpath.com/news/f622ebda26ad0e1f/the-lasting-impact-of-the-cross-trial-on-gej-cancer-care-targeted-oncology 2024-11-15T08:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/ae07d8d33c4a606b/99-of-mounjaro-zepbound-patients-remained-diabetes-free-even-at-3-years-eli-lilly-s 2024-11-15T08:00:14+00:00 weekly 0.7 https://trial.medpath.com/news/4a1a05f94f4e7d62/plus-therapeutics-announces-fda-approval-for-phase-1-trial-of-rhenium-186re-barchart-com 2024-11-15T07:44:07+00:00 weekly 0.7 https://trial.medpath.com/news/89e204224a2e7aa0/a-study-within-a-trial-swat-of-clinical-trial-feasibility-and-barriers-to-recruitment-in-the 2024-11-15T07:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/803acb250f50e813/ema-gives-partial-go-ahead-for-first-alzheimer-s-treatment-in-eu-belganewsagency-eu 2024-11-15T07:39:12+00:00 weekly 0.7 https://trial.medpath.com/news/1862f2a50b8a298b/pds-biotechnology-corp-pdsb-q3-2024-earnings-call-highlights-navigating-financial 2024-11-15T07:21:33+00:00 weekly 0.7 https://trial.medpath.com/news/088a8fc722def5f5/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic 2024-11-15T06:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/4e157b41c0768c25/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic 2024-11-15T06:54:41+00:00 weekly 0.7 https://trial.medpath.com/news/525013e586d04528/fda-approves-ptc-s-kebilidi-as-first-gene-therapy-to-treat-aadc-deficiency-rttnews 2024-11-15T06:15:17+00:00 weekly 0.7 https://trial.medpath.com/news/4467edb689653586/fortress-biotech-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-15T06:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/25eca18cded0da07/select-mds-1-trial-of-tamibarotene-misses-primary-end-point-in-mds 2024-11-15T06:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/ec19d1c88ced22a0/balancing-clinical-data-and-real-world-insights-in-cml-treatment-targeted-oncology 2024-11-15T06:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/71ab8be126951acb/sandoz-wins-eu-approval-for-eylea-biosimilar-to-treat-vision-loss-launch-set-for-2025 2024-11-15T06:03:46+00:00 weekly 0.7 https://trial.medpath.com/news/0b4d52e269665be3/press-release-dupixent-sbla-accepted-for-fda-review-for-globenewswire 2024-11-15T06:03:12+00:00 weekly 0.7 https://trial.medpath.com/news/cbfa6746a9f28100/pediatric-glp-1-prescriptions-surge-sevenfold-as-experts-navigate-benefits-and-risks 2024-11-15T05:50:23+00:00 weekly 0.7 https://trial.medpath.com/news/9b7633ab74c23409/sagimet-biosciences-inc-strategic-advancements-and-financial-robustness-drive-buy-rating 2024-11-15T05:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/ae8861df2c1cfc1d/gsk-announces-positive-results-from-head-to-head-dreamm-7-phase-iii-trial-of-blenrep-in 2024-11-15T05:29:31+00:00 weekly 0.7 https://trial.medpath.com/news/25a81f8c6533864a/q3-2024-biomx-inc-earnings-call-yahoo-finance 2024-11-15T05:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/ded6f6cc6d990fb6/ptc-gets-us-fda-approval-for-brain-delivered-gene-therapy-citeline 2024-11-15T05:05:02+00:00 weekly 0.7 https://trial.medpath.com/news/32e0eb4dd61b5190/patient-centric-trial-design-key-strategies-for-improving-clinical-research-success 2024-11-15T05:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/b0150e547a0eadb5/elutia-inc-reports-strong-q3-results-prepares-for-major-product-launch-tipranks-com 2024-11-15T05:00:31+00:00 weekly 0.7 https://trial.medpath.com/news/63f15d2fa0ef82ab/eu-regulator-backs-eisai-biogen-alzheimer-s-drug-the-hindu 2024-11-15T04:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/52250217de90ee7a/impact-of-l-carnitine-supplementation-on-gastric-emptying-and-bowel-function-in-pediatric 2024-11-15T04:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/fbad50b42894090c/munich-to-host-clinical-trials-in-oncology-europe-2024-ai-strategy-and-patient-experience-take-center-stage 2024-11-15T04:11:15+00:00 weekly 0.7 https://trial.medpath.com/news/227cf2045c9379d3/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-placera 2024-11-15T04:06:20+00:00 weekly 0.7 https://trial.medpath.com/news/71066f01b6dd791b/marinus-pharmaceuticals-lays-off-45-of-employees-biospace 2024-11-15T04:06:01+00:00 weekly 0.7 https://trial.medpath.com/news/7dcfa64f7b5f543b/researchers-present-updated-os-analysis-of-perla-trial-in-metastatic-nsclc 2024-11-15T04:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/cb3d15b5edd69462/tivic-completes-enrollment-in-nerve-stim-trial-massdevice 2024-11-15T04:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/ff75a1a129818668/angiotensin-ii-and-thromboembolism-reading-the-fine-print-critical-care-medicine 2024-11-15T04:04:05+00:00 weekly 0.7 https://trial.medpath.com/news/f6b3734aa21814a5/biotech-leaders-share-three-critical-strategies-for-r-d-success-in-drug-development 2024-11-15T04:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/410a86233118a5a6/first-brain-delivered-gene-therapy-approved-for-aadc-deficiency-medpage-today 2024-11-15T03:57:37+00:00 weekly 0.7 https://trial.medpath.com/news/acffa43fd0e2d67b/gh-research-reports-deeper-losses-as-dmt-clinical-trial-costs-mount 2024-11-15T03:41:21+00:00 weekly 0.7 https://trial.medpath.com/news/5c53003a381afd86/delgocitinib-approved-for-adults-with-moderate-to-severe-che-in-switzerland 2024-11-15T03:35:40+00:00 weekly 0.7 https://trial.medpath.com/news/f9bcc1126c4d17f2/ultrasound-device-garners-fda-de-novo-nod-for-kidney-stone-clearance 2024-11-15T03:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/bb39f76452bb05b3/tonix-seeks-fda-approval-for-sleep-enhancing-drug-for-fibromyalgia 2024-11-15T03:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/bf5c9e592962f2e2/ai-tool-sees-cancer-gene-signatures-in-biopsy-images-news-center-stanford-medicine 2024-11-15T03:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/9cdb0767e211b78d/phase-3-study-finds-inebilizumab-effective-for-immunoglobulin-g4-related-disease 2024-11-15T02:40:10+00:00 weekly 0.7 https://trial.medpath.com/news/419f11497f949c93/allogene-shares-target-cut-rating-held-on-trial-enrollment-issue-investing-com 2024-11-15T02:11:21+00:00 weekly 0.7 https://trial.medpath.com/news/db0bec851b073bbe/leqembi-secures-ema-thumbs-up-for-narrower-indication-citeline 2024-11-15T01:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/623472aa34a8302f/pds-biotechnology-price-target-lowered-to-4-50-from-7-at-alliance-global-partners 2024-11-15T01:33:16+00:00 weekly 0.7 https://trial.medpath.com/news/c69014a12e7610ce/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-pr-newswire 2024-11-15T01:16:24+00:00 weekly 0.7 https://trial.medpath.com/news/7544c3d93a7bb7c8/innocare-announces-first-subject-dosed-in-the-phase-iii-registrational-trial-of-tyk2 2024-11-15T00:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/df75cea297934b97/merck-is-paying-588m-for-potential-successor-to-cancer-drug-juggernaut-keytruda 2024-11-15T00:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/d78dadee94f153bf/could-ozempic-help-treat-substance-use-disorder-women-s-health 2024-11-15T00:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/f2e81db79235492b/fda-approves-revuforj-revumenib-for-the-treatment-of-adult-and-pediatric-patients-with-relapsed-or-refractory-acute-leukemia-with-a-kmt2a-translocation 2024-11-15T00:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/13f270837c0524ad/nhs-launches-search-for-150000-volunteers-to-help-transform-cancer-treatment 2024-11-15T00:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/ce0d5fa8ca55afbb/va-launches-progress-study-to-enhance-prostate-cancer-screening-with-genetic-testing 2024-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9eddf24d9a351378/first-in-human-study-of-bat4406f-shows-promise-for-nmosd-treatment 2024-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cf9fad30280d8396/fda-approval-insights-zolbetuximab-for-cldn18-2-her2-negative-gastric-and-gej 2024-11-14T23:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/2dfe9ab027d2f863/new-bimzelx-r-bimekizumab-bkzx-data-at-acr-convergence-2024-highlights-ucb 2024-11-14T23:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/4dc2f2f946df1cac/fda-approves-nilotinib-tablets-without-mealtime-restrictions-for-cml-onclive 2024-11-14T22:56:19+00:00 weekly 0.7 https://trial.medpath.com/news/a9d632d48ad59d4f/fda-approves-danziten-for-chronic-myeloid-leukemia-without-mealtime-restrictions 2024-11-14T22:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/7645c62180a5d82a/vivolta-partners-with-neurochase-to-manufacture-electrospun-microcatheters-for-delivery-of 2024-11-14T22:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/427e9f8e70a4e904/ptc-therapeutics-wins-first-fda-approval-for-a-gene-therapy-dosed-directly-into-the-brain 2024-11-14T22:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/955ff48c616b02a2/larger-study-supports-safety-of-tetracyclines-during-early-pregnancy-medpage-today 2024-11-14T22:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/0be8902e00c7e714/drug-being-tested-to-address-side-effects-of-cancer-treatment-nebraska-medicine 2024-11-14T22:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/700dc407df2548d7/osteal-therapeutics-announces-positive-12-month-results-from-the-apex-clinical-trial 2024-11-14T22:20:49+00:00 weekly 0.7 https://trial.medpath.com/news/cdd63d376a5841c5/tirzepatide-demonstrates-significant-benefits-for-patients-with-pre-diabetes-obesity-over 2024-11-14T22:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/5b5b623d8e9447b8/world-diabetes-day-2024-looking-back-at-progress-for-cell-and-gene-therapy-cgtlive-r 2024-11-14T22:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/22e3bf109a6d10ca/nilotinib-tablets-approved-by-fda-for-ph-cml-in-chronic-phase-cancer-network 2024-11-14T21:59:42+00:00 weekly 0.7 https://trial.medpath.com/news/b503777a40cf3782/panbela-provides-business-update-and-reports-q3-2024-financial-results 2024-11-14T21:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/80bc7b1318bbf283/fortress-biotech-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T21:57:38+00:00 weekly 0.7 https://trial.medpath.com/news/3cf13c47387ff1bc/precigen-reports-third-quarter-2024-financial-results-and-business-updates-morningstar 2024-11-14T21:57:35+00:00 weekly 0.7 https://trial.medpath.com/news/2021bc1f8006fce6/bayer-to-present-new-prespecified-subgroup-analyses-from-investigational-phase-iii 2024-11-14T21:55:40+00:00 weekly 0.7 https://trial.medpath.com/news/a257ad389fddec84/j-j-medtech-advances-into-surgical-robotics-with-ottava-clinical-trials-zenopa 2024-11-14T21:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/fdc439729b7acf38/2024-updates-in-gi-cancer-feature-flot-combinations-restricted-fda-approvals-by-pd 2024-11-14T21:49:58+00:00 weekly 0.7 https://trial.medpath.com/news/c67526bcc9280813/osteal-therapeutics-announces-positive-12-month-results-globenewswire 2024-11-14T21:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/b952c993ba0a04f0/fda-approves-novel-gene-therapy-for-rare-neurometabolic-disorder-healio 2024-11-14T21:41:53+00:00 weekly 0.7 https://trial.medpath.com/news/90fe66f8898bfa4d/q-a-first-patient-dosed-in-iggenix-accelerate-peanut-phase-1-clinical-trial-healio 2024-11-14T21:41:52+00:00 weekly 0.7 https://trial.medpath.com/news/4e9e7b65b389a783/eisai-wins-over-european-regulators-on-alzheimer-s-drug-leqembi-biopharma-dive 2024-11-14T21:41:05+00:00 weekly 0.7 https://trial.medpath.com/news/725dbdf3323d9f0f/precigen-reports-third-quarter-2024-financial-results-and-business-updates-stock-titan 2024-11-14T21:39:35+00:00 weekly 0.7 https://trial.medpath.com/news/e74cee14b69aa7d3/nrx-pharmaceuticals-nasdaq-nrxp-reports-third-quarter-and-year-to-date-2024 2024-11-14T21:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/3ff91e8114038426/genelux-corporation-reports-third-quarter-2024-financial-globenewswire 2024-11-14T21:27:25+00:00 weekly 0.7 https://trial.medpath.com/news/0cd83fcfba214675/ticker-biogen-alzheimer-s-drug-gets-second-look-in-eu-ford-takes-165m-hit-on-slow-recall 2024-11-14T21:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/5c3652004d31563c/enlivex-announces-the-dosing-of-the-first-patient-in-a-phase-i-clinical-trial-evaluating 2024-11-14T21:18:43+00:00 weekly 0.7 https://trial.medpath.com/news/8a2a8fc26bd450d9/amgen-presents-new-data-across-rare-inflammatory-diseases-at-acr-2024-stock-titan 2024-11-14T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/ca14e50ce19d81f9/crinetics-unveils-breakthrough-cancer-drug-platform-reports-positive-phase-2-trial-results 2024-11-14T21:17:36+00:00 weekly 0.7 https://trial.medpath.com/news/ce08466731948b84/avenue-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T21:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/70cadc8d759bf22a/dare-bioscience-reports-third-quarter-2024-financial-results-and-provides-company-update 2024-11-14T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/9f8e07c8ad217cd8/amgen-presents-new-data-across-rare-inflammatory-diseases-at-acr-2024 2024-11-14T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/778ddb1056a52f5f/nrx-pharmaceuticals-nasdaq-nrxp-reports-third-quarter-and-year-to-date-2024 2024-11-14T21:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/b3d0e9956d8b5dcc/azurity-pharmaceuticals-inc-announces-fda-approval-of-danziten 2024-11-14T21:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/c2ea3d4129dac2ce/mirdametinib-yields-significant-responses-and-hrqol-improvements-in-nf1-pn 2024-11-14T21:04:42+00:00 weekly 0.7 https://trial.medpath.com/news/a684d924b0c50d30/fda-approval-sought-for-dato-dxd-in-egfr-mutated-nsclc-targeted-oncology 2024-11-14T21:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/5db24840b4fdfec6/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-of 2024-11-14T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/d1c6d2ca85d82738/azurity-pharmaceuticals-inc-announces-fda-approval-of-danziten 2024-11-14T21:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/d39e02da0af03e8e/fda-grants-accelerated-approval-for-ptc-s-aadc-deficiency-gene-therapy-yahoo-finance 2024-11-14T20:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/89d604a575e69aff/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-14T20:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/f9123ea5ecea53cf/cell-therapy-weekly-fda-approves-car-t-therapy-for-r-r-b-all-regmednet 2024-11-14T20:41:32+00:00 weekly 0.7 https://trial.medpath.com/news/67d7e90784d4eefc/sacituzumab-tirumotecan-shows-antitumor-activity-in-previously-treated-endometrial-onclive 2024-11-14T20:14:49+00:00 weekly 0.7 https://trial.medpath.com/news/70c971d2e48c6748/tirzepatide-prevents-type-2-diabetes-in-99-of-prediabetic-patients-for-3-years 2024-11-14T20:11:23+00:00 weekly 0.7 https://trial.medpath.com/news/bffac7d7cc29bef6/a-phase-3-trial-of-amezalpat-in-advanced-liver-cancer-receives-study-may-proceed-letter 2024-11-14T20:08:12+00:00 weekly 0.7 https://trial.medpath.com/news/6d4838ed4be89c86/fda-advisory-committee-outlines-informed-consent-best-practices-jd-supra 2024-11-14T19:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/97706bc029d0c43f/blood-test-breakthrough-revolutionizing-postpartum-depression-walb 2024-11-14T19:58:27+00:00 weekly 0.7 https://trial.medpath.com/news/6712e030198fcece/recommendations-for-detection-assessment-and-management-of-suspected-drug-induced 2024-11-14T19:50:31+00:00 weekly 0.7 https://trial.medpath.com/news/6d50d2d8c0ee50cd/leqembi-secures-ema-thumbs-up-for-narrower-indication 2024-11-14T19:49:38+00:00 weekly 0.7 https://trial.medpath.com/news/bdf6c7b8ea7d5ebb/european-watchdog-partially-approves-new-alzheimer-s-drug-barron-s 2024-11-14T19:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/b818bce7f760c8f9/amgen-speaks-out-about-bone-density-concerns-with-obesity-drug-clinical-trials-arena 2024-11-14T19:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/5983abe0dc04746f/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-r-acute 2024-11-14T19:43:08+00:00 weekly 0.7 https://trial.medpath.com/news/32b337260824c17f/european-committee-takes-a-second-look-at-alzheimer-s-drug-and-now-says-it-should-be-approved 2024-11-14T19:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/d903b22c49bff977/medicus-pharma-ceo-dr-raza-bokhari-on-4m-nasdaq-ipo-phase-2-trial 2024-11-14T19:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/eac525f7b48f5e90/fda-grants-conditional-approval-for-ptc-therapeutics-gene-therapy-as-first-ever-with 2024-11-14T19:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/3595575971397d8e/nivolumab-plus-chemotherapy-enhances-responses-is-well-tolerated-in-hodgkin-lymphoma 2024-11-14T19:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/d70bb467eb608881/everything-you-need-to-know-about-nice-s-decisions-on-game-changing-alzheimer-s-drugs 2024-11-14T19:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/d258132ba57a029a/fda-approves-kebilidi-as-first-gene-therapy-to-treat-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-14T19:01:15+00:00 weekly 0.7 https://trial.medpath.com/news/1b56441fc1f53eef/european-watchdog-partially-approves-new-alzheimer-s-drug-ndtv 2024-11-14T18:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/f1738a25221f5e8e/eisai-biogen-s-alzheimer-s-drug-lecanemab-wins-key-eu-panel-backing-after-appeal 2024-11-14T18:40:42+00:00 weekly 0.7 https://trial.medpath.com/news/0474b3ec4f051ebb/ema-rethinks-stance-committee-now-recommends-leqembi-for-alzheimer-s-disease 2024-11-14T18:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/6486346555f4513f/kronos-mulls-strategic-alternatives-after-axing-cancer-drug-development 2024-11-14T18:37:36+00:00 weekly 0.7 https://trial.medpath.com/news/983f4b632ec3e994/eu-reverses-course-approval-for-breakthrough-alzheimer-s-drug-leqembi-recommended 2024-11-14T18:31:38+00:00 weekly 0.7 https://trial.medpath.com/news/423ed7956f44f85a/nivolumab-and-avd-the-new-standard-in-hodgkin-lymphoma-national-cancer-institute 2024-11-14T18:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/9e397ec5df7bd7a0/cybin-posts-second-quarter-loss-widens-as-clinical-trials-advance-green-market-report 2024-11-14T17:55:21+00:00 weekly 0.7 https://trial.medpath.com/news/9560fd7c2798d800/pds-biotechnology-corporation-provides-clinical-programs-update-marketscreener 2024-11-14T17:44:09+00:00 weekly 0.7 https://trial.medpath.com/news/132197587a56034e/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-markets-data 2024-11-14T17:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/cfdf0840579f61ae/kebilidi-aadc-deficiency-gene-therapy-now-approved-by-fda 2024-11-14T17:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/5a1d000370c08035/sanofi-s-sarclisa-recommended-for-eu-approval-marketscreener 2024-11-14T17:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/d51b027633fb2850/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-meeting 2024-11-14T17:35:59+00:00 weekly 0.7 https://trial.medpath.com/news/80e37f12cdc75b50/sanofi-s-sarclisa-recommended-for-eu-approval-morningstar 2024-11-14T17:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/e31986e9fb7e6124/wet-amd-therapeutics-technologies-raising-the-ceiling-for-functional-visual-outcomes 2024-11-14T17:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/0b849b5e84472616/mounjaro-lowers-type-2-diabetes-risk-in-phase-3-trial-study-becker-s-hospital-review 2024-11-14T17:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/4def281835cf6249/press-release-sarclisa-recommended-for-eu-approval-by-the-chmp-to-treat-transplant 2024-11-14T17:18:18+00:00 weekly 0.7 https://trial.medpath.com/news/35254c624069f51a/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-markets-data 2024-11-14T17:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/841f89c2f80ea3dd/eftilagimod-alpha-plus-pembrolizumab-chemo-generates-improved-survival-trends-in 2024-11-14T17:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/a0f30e8bed7bdbb5/earnings-call-polypid-reports-on-d-plex100-trial-and-financials-investing-com-uk 2024-11-14T17:17:18+00:00 weekly 0.7 https://trial.medpath.com/news/ce7e39dea84f8d09/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-stock-titan 2024-11-14T17:17:06+00:00 weekly 0.7 https://trial.medpath.com/news/f0ac72509f8ba68a/eu-backs-eisai-alzheimer-s-drug-in-reversal-of-earlier-rejection-bnn-bloomberg 2024-11-14T17:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/1c19e3099cda9f70/eu-backs-leqembi-a-breakthrough-in-alzheimer-s-treatment-health-devdiscourse 2024-11-14T17:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/822c7d8b7e333cc4/new-alzheimer-s-prevention-trial-receives-74-5-million-nih-grant 2024-11-14T17:11:36+00:00 weekly 0.7 https://trial.medpath.com/news/eb6c5f499186fd8e/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-pr-newswire 2024-11-14T17:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/21ac4e0ac4d351b4/fda-clears-icobrain-aria-first-ai-tool-for-safer-aria-detection-in-alzheimer-treatment 2024-11-14T17:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/c53f231e90b2543c/xeltis-wins-fda-breakthrough-status-enrols-first-patient-in-pivotal-trial 2024-11-14T17:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/166dcaeff44d517e/tau-modification-drugs-take-a-hit-with-negative-trial-alzforum 2024-11-14T16:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/fd124b5708ea34fa/study-finds-weakness-in-drug-resistant-tuberculosis-pathogens-news-medical 2024-11-14T16:47:49+00:00 weekly 0.7 https://trial.medpath.com/news/0f95cbaa7dfeee4b/ptc-wins-us-approval-of-gene-therapy-for-fatal-enzyme-disorder-biopharma-dive 2024-11-14T16:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/dd7ceb7e1884b418/the-breast-cancer-after-care-better-care-programme-to-improve-breast-cancer-follow-up 2024-11-14T16:47:14+00:00 weekly 0.7 https://trial.medpath.com/news/9e586eaca13ba3a0/press-release-sarclisa-recommended-for-eu-approval-by-the-globenewswire 2024-11-14T16:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/1c746c766289e8e1/microbion-reports-topline-data-from-phase-ii-study-of-dfi-therapy-clinical-trials-arena 2024-11-14T16:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/330ed847c6f3c3fc/sanofi-formation-and-openai-design-ai-tool-to-slash-clinical-trial-timelines-oodaloop 2024-11-14T16:35:30+00:00 weekly 0.7 https://trial.medpath.com/news/cf5c540fb9aea966/are-glp-1-drugs-really-for-everybody-nature-medicine 2024-11-14T16:29:22+00:00 weekly 0.7 https://trial.medpath.com/news/c87cdb95f7323f58/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu 2024-11-14T16:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/b96a9180c6a95810/fda-breakthrough-device-decisions-rebound-after-recent-declines-medtech-dive 2024-11-14T16:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/506d12111dda44a8/xeltis-wins-fda-breakthrough-status-enrols-first-patient-in-pivotal-trial-clinical-trials-arena 2024-11-14T16:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/ab00b7131837ca57/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints 2024-11-14T16:00:28+00:00 weekly 0.7 https://trial.medpath.com/news/a7f511651cd21c7e/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints 2024-11-14T16:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/7a161819be4c4621/ptc-nets-aadc-gene-therapy-approval-first-brain-delivered-gene-therapy-in-u-s 2024-11-14T15:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/636af335ceeb7afb/levicept-presents-positive-phase-ii-data-for-novel-neurotrophin-3-inhibitor-levi-04-morningstar 2024-11-14T15:53:18+00:00 weekly 0.7 https://trial.medpath.com/news/f7fc6193e2af8f06/khondrion-receives-fda-clearance-of-ind-application-for-pivotal-phase-3-clinical-trial-of-biospace 2024-11-14T15:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/2ddaa2188e631069/new-weight-loss-drug-cuts-appetite-without-causing-muscle-loss-study-finds 2024-11-14T15:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/b3448b3d7b51cea6/reach-completes-phase-ii-of-future-force-energy-campaign-with-u-s-air-force-morningstar 2024-11-14T15:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/212ae0c0896f31ee/bladder-cancer-biomarkers-promise-improved-survival-inside-precision-medicine 2024-11-14T15:38:31+00:00 weekly 0.7 https://trial.medpath.com/news/0354f4cf7a972963/nrxbf-gains-another-governmental-designation-zacks-small-cap-research 2024-11-14T15:36:49+00:00 weekly 0.7 https://trial.medpath.com/news/5cfa2fb3697fa834/fda-approves-gene-therapy-to-treat-aadc-deficiency 2024-11-14T15:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/e19771b63b31eace/lilly-reports-trial-results-of-tirzepatide-for-treating-obesity-and-pre-diabetes 2024-11-14T15:31:33+00:00 weekly 0.7 https://trial.medpath.com/news/b88f5f9a5432dbcd/advanced-breast-imaging-reduces-need-for-axillary-lymph-node-dissection-in-breast-cancer 2024-11-14T15:30:23+00:00 weekly 0.7 https://trial.medpath.com/news/711169386675662c/cybin-to-present-12-month-phase-2-data-for-cyb003-in-major-depressive-disorder-on 2024-11-14T15:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/f48b85cb77909b9c/sagimet-biosciences-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-14T15:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/c6bc34edcb191722/evolution-of-egfr-inhibition-marks-transformative-era-in-lung-cancer-treatment 2024-11-14T15:25:22+00:00 weekly 0.7 https://trial.medpath.com/news/054ac2e2b98ad21a/in-case-you-missed-it-roundup-from-esmo-congress-2024-the-asco-post 2024-11-14T15:21:44+00:00 weekly 0.7 https://trial.medpath.com/news/d2e6763ac89586db/fda-approves-gene-therapy-for-debilitating-enzyme-deficiency 2024-11-14T15:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/12eb5960f01fb5ea/levicept-presents-positive-phase-ii-data-for-novel-globenewswire 2024-11-14T15:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/4bd671ff3a18a684/nipocalimab-demonstrates-significant-clinical-improvement-in-disease-activity-and-igg 2024-11-14T15:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/435f7459542a48fe/ptc-therapeutics-gains-buy-rating-following-fda-approval-of-groundbreaking-gene 2024-11-14T15:13:14+00:00 weekly 0.7 https://trial.medpath.com/news/149f88f07e80bad0/fda-oks-clinical-trial-of-ata-200-gene-therapy-for-lgmd-children 2024-11-14T15:10:55+00:00 weekly 0.7 https://trial.medpath.com/news/110313f1307a9363/review-approving-using-jak-inhibitors-for-better-alopecia-areata-outcomes 2024-11-14T15:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/9c3adacc32f62ae6/cabaletta-bio-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-14T15:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/43d67b61ca05ac8a/targeted-combination-shows-promise-in-metastatic-kidney-cancer-medpage-today 2024-11-14T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/67aa1456f89ec699/clinical-trial-shows-positive-results-for-potential-treatment-to-combat-a-challenging-rare-disease 2024-11-14T15:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/38dd076b96bda5ff/fda-drug-rejections-have-one-fatal-flaw-realclearhealth 2024-11-14T15:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/5e0b01b1ddeb8ba9/adaptimmune-outlines-new-strategy-amid-tecelra-launch 2024-11-14T15:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/5db602eae333ec82/fda-approves-eladocagene-exuparvovec-tneq-for-treatment-of-aadc-deficiency 2024-11-14T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/28cd7102382da298/leqembi-side-effects-no-worse-in-clinical-use-than-they-were-in-trial-alzforum 2024-11-14T14:57:53+00:00 weekly 0.7 https://trial.medpath.com/news/8fcdc51e165134d3/a-single-crispr-treatment-could-replace-a-lifetime-of-daily-treatment-in-hereditary-angioedema 2024-11-14T14:50:03+00:00 weekly 0.7 https://trial.medpath.com/news/acccb2bffda71efb/widely-integrated-services-in-home-wish-for-homebound-older-adults-a-study-protocol-for 2024-11-14T14:36:57+00:00 weekly 0.7 https://trial.medpath.com/news/eea1ef599b60f70d/positive-phase-ii-top-line-data-highlights-omadacycline-s-potential-in-the-ntm-market 2024-11-14T14:36:15+00:00 weekly 0.7 https://trial.medpath.com/news/87abaafdc4598c6e/pharmala-reaches-agreement-in-principle-to-supply-mdma-to-globenewswire 2024-11-14T14:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/e7741c01c87ff127/sagimet-biosciences-inc-sec-10-q-report-tradingview 2024-11-14T14:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/a333cf7b8362bfb7/candel-therapeutics-inc-sec-10-q-report-tradingview 2024-11-14T14:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/1478afe674ae5222/fda-grants-accelerated-approval-for-ptc-s-aadc-deficiency-gene-therapy 2024-11-14T14:21:03+00:00 weekly 0.7 https://trial.medpath.com/news/002fafac3382558f/mabwell-s-novel-nectin-4-targeting-adc-9mw2821-approved-for-2-clinical-trials-by-cde-of-nmpa 2024-11-14T14:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/e806187afa1e90b5/actinium-pharmaceuticals-reports-data-from-phase-iii-trial-of-aml-treatment-msn 2024-11-14T14:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/6413b417b0d4d5d9/mabwell-s-novel-nectin-4-targeting-adc-9mw2821-approved-for-2-clinical-trials-by-cde-of-nmpa 2024-11-14T14:07:04+00:00 weekly 0.7 https://trial.medpath.com/news/3bd61518a6644d85/new-study-looks-at-why-cancer-treatments-cause-heart-damage-uc-san-francisco 2024-11-14T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/news/b40f7e1232ef478a/malaria-developing-resistance-to-drug-that-saves-children-s-lives 2024-11-14T14:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/87d6b51bbffbefde/pds-biotechnology-corp-reports-q3-2024-gaap-eps-of-0-29-missi-gurufocus 2024-11-14T13:55:16+00:00 weekly 0.7 https://trial.medpath.com/news/4947a1e947725b11/fda-approves-new-car-t-therapy-for-adults-with-acute-leukemia-cancer-health 2024-11-14T13:54:26+00:00 weekly 0.7 https://trial.medpath.com/news/ec0839eb674737db/envoy-medical-reports-third-quarter-2024-results-and-other-exciting-events 2024-11-14T13:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/eee5275b5d3a495f/medistim-launches-clinical-study-on-ttfm-and-hfus-in-vascular-surgery-finansavisen 2024-11-14T13:47:55+00:00 weekly 0.7 https://trial.medpath.com/news/fcf4524e83a25525/missing-outcome-data-in-randomised-clinical-trials-of-psychological-interventions-bmc-psychiatry 2024-11-14T13:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/54eb828adc65f130/chemomab-therapeutics-announces-third-quarter-2024-financial-results-and-provides 2024-11-14T13:39:02+00:00 weekly 0.7 https://trial.medpath.com/news/94804350f50f290c/amgen-defends-obesity-drug-amid-bone-concerns-stat-news 2024-11-14T13:38:24+00:00 weekly 0.7 https://trial.medpath.com/news/65e47c31b39253ff/calidi-biotherapeutics-raises-7-5m-in-public-offering-for-clinical-trials-cldi-stock-news 2024-11-14T13:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/0e9f000e45947149/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-pr-newswire 2024-11-14T13:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/1325ea7bdbaeefcd/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-yahoo-finance 2024-11-14T13:21:45+00:00 weekly 0.7 https://trial.medpath.com/news/5ad9bc50146c8290/pds-biotechnology-biotech-provides-clinical-programs-update-and-reports-third-quarter 2024-11-14T13:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/f89f9aa140229f00/moleculin-biotech-accelerates-phase-3-aml-trial-data-timeline-to-h2-2025-mbrx-stock-news 2024-11-14T13:19:18+00:00 weekly 0.7 https://trial.medpath.com/news/c3a336969bc2a03e/immutep-s-efti-shows-excellent-survival-data-from-insight-003-trial-in-non-small-cell-lung-cancer 2024-11-14T13:18:06+00:00 weekly 0.7 https://trial.medpath.com/news/c6a58f9e4e18733c/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-meeting 2024-11-14T13:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/c51323b10dbfaf53/ptc-therapeutics-gets-fda-nod-for-kebilidi-to-treat-aadc-deficiency 2024-11-14T13:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/0bf513552467f2d8/sagimet-biosciences-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-14T13:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/224b9d113d02dac7/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-yahoo-finance 2024-11-14T13:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/5d6d73eba7ba8583/fda-approves-expanded-age-indication-for-nerivio-migraine-device-in-pediatric-patients 2024-11-14T13:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/ddc89a91854241db/candel-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T13:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/a17cbd39f217b346/sagimet-s-denifanstat-earns-fda-breakthrough-status-reports-170m-cash-position 2024-11-14T13:01:06+00:00 weekly 0.7 https://trial.medpath.com/news/48313cb01af9588c/ptc-wins-first-fda-nod-for-direct-to-brain-gene-therapy-targets-ultrarare-disease 2024-11-14T12:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/8eb60af2b62a3b9e/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-pr-newswire 2024-11-14T12:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/1a8842c2d33f39e7/khondrion-receives-fda-clearance-of-ind-application-for-pivotal-phase-3-clinical-trial-morningstar 2024-11-14T12:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/e3b76b82ca64a484/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-stock-titan 2024-11-14T12:40:01+00:00 weekly 0.7 https://trial.medpath.com/news/29f08555ea232f23/merck-kgaa-abbisko-share-positive-phase-3-results-for-pimicotinib-in-rare-tumour-type 2024-11-14T12:35:18+00:00 weekly 0.7 https://trial.medpath.com/news/a19ddf20d68f07f0/intelligent-gears-up-for-fda-approval-of-fingerprint-drug-detection-device-yahoo-finance 2024-11-14T12:21:35+00:00 weekly 0.7 https://trial.medpath.com/news/1a5dad200c654fc8/cabaletta-bio-expands-clinical-trials-to-40-sites-reports-183m-cash-position-caba-stock-news 2024-11-14T12:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/26bff7d4accd1fd1/appili-therapeutics-reports-fda-approved-drug-launch-advances-vaccine-pipeline-in-q2 2024-11-14T12:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/b86fcafc3e558516/fda-accepts-abeona-therapeutics-bla-for-epidermolysis-bullosa-gene-therapy-pz-cel 2024-11-14T12:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/e034c0f9589c942d/protalix-biotherapeutics-reports-third-quarter-2024-financial-and-business-results 2024-11-14T12:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/47c91c1c529de4fd/khondrion-receives-fda-clearance-of-ind-application-for-globenewswire 2024-11-14T12:14:42+00:00 weekly 0.7 https://trial.medpath.com/news/bd2e3cfa5c8b9550/chemomab-therapeutics-announces-third-quarter-2024-globenewswire 2024-11-14T12:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/84ad3e6009e9cdde/eli-lilly-conclusive-phase-iii-trial-on-tirzepatide-marketscreener 2024-11-14T12:06:11+00:00 weekly 0.7 https://trial.medpath.com/news/c73822f6fe7293bd/fda-authorizes-the-first-ai-driven-mri-solution-for-safer-alzheimer-s-treatment-biospace 2024-11-14T12:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/a835eb2b966b6e33/aha-study-reveals-major-gap-in-sexual-health-guidance-for-cardiovascular-patients 2024-11-14T11:59:07+00:00 weekly 0.7 https://trial.medpath.com/news/a8d78047a56743ca/xeltis-announces-fda-breakthrough-device-designation-for-axesstm-and-first-patient 2024-11-14T11:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/faea01501b8d2855/mild-alzheimer-s-patients-won-t-save-cassava-sciences-drug-stat-news 2024-11-14T11:33:14+00:00 weekly 0.7 https://trial.medpath.com/news/6df141515452c345/rhythm-pharmaceuticals-announces-publication-of-results-globenewswire 2024-11-14T11:33:13+00:00 weekly 0.7 https://trial.medpath.com/news/4443ac719677a6d1/neurogene-eyes-phase-3-registrational-study-for-gene-therapy-ngn-401-following 2024-11-14T11:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/db68a8751bad12a9/new-therapeutic-vaccine-gives-hope-against-an-aggressive-breast-cancer 2024-11-14T11:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/137aa4e456a074b4/caliway-s-drug-molecule-cbl-514-to-treat-dercum-s-disease-receives-ema-orphan-drug-designation 2024-11-14T10:29:48+00:00 weekly 0.7 https://trial.medpath.com/news/2b9881cb226a835f/cell-therapy-fights-lethal-childhood-brain-cancer-in-stanford-medicine-trial 2024-11-14T10:02:43+00:00 weekly 0.7 https://trial.medpath.com/news/d98f74ba26f99401/car-t-cell-therapy-breakthroughs-bring-new-hope-for-treating-solid-tumors-news-medical 2024-11-14T09:44:27+00:00 weekly 0.7 https://trial.medpath.com/news/2222e82d2a22b593/leaf-trauma-an-intersectoral-prospective-multicenter-study-assessing-quality-of-life-and-plos 2024-11-14T08:38:41+00:00 weekly 0.7 https://trial.medpath.com/news/e7dfe9d1b463e692/syros-slammed-by-phase-iii-data-with-tamibarotene-in-mds-bioworld 2024-11-14T08:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/bc572cc7bb7c1ffa/around-the-helix-cell-and-gene-therapy-company-updates-november-13-2024 2024-11-14T08:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/57eac883d889b29b/syros-stock-craters-after-lead-cancer-therapy-flops-in-phase-iii-trial 2024-11-14T08:05:28+00:00 weekly 0.7 https://trial.medpath.com/news/6b776acff27f2f13/implantica-submits-fda-pma-application-clinical-module-2-for-refluxstoptm-for-u-s-market-approval 2024-11-14T07:51:33+00:00 weekly 0.7 https://trial.medpath.com/news/2443ba9f90c8b542/treatment-landscape-analysis-current-therapeutic-approaches-for-grade-3-well-differentiated-neuroendocrine-tumors 2024-11-14T07:40:08+00:00 weekly 0.7 https://trial.medpath.com/news/e900a03164de82f8/ptc-therapeutics-announces-fda-approval-of-aadc-deficiency-gene-therapy 2024-11-14T07:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/bd10d85b6d17b089/information-about-the-annual-report-2023-2024-diamyd-medical-ab-cision-news 2024-11-14T07:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/15449cb73d05caf8/japan-adopts-early-approval-scheme-for-infectious-disease-drugs-citeline 2024-11-14T07:29:48+00:00 weekly 0.7 https://trial.medpath.com/news/c757140c0798e4c8/interim-report-for-the-period-july-september-2024-bioarctic-cision-news 2024-11-14T07:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/eb4345a584e86d72/jaguar-health-inc-jagx-q3-2024-earnings-call-highlights-reven-gurufocus 2024-11-14T07:25:42+00:00 weekly 0.7 https://trial.medpath.com/news/6154f19e0836e14b/ptc-gets-fda-okay-for-first-brain-delivered-gene-therapy-pharmaphorum 2024-11-14T07:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/4df9e66c8184222c/adaptimmune-nears-second-approval-for-tcr-t-therapy-european-biotechnology 2024-11-14T07:24:58+00:00 weekly 0.7 https://trial.medpath.com/news/9504b30ab07b63b6/bergenbio-asa-fra-7bg0-q3-2024-earnings-call-highlights-strat-gurufocus 2024-11-14T07:23:52+00:00 weekly 0.7 https://trial.medpath.com/news/9da39f3bc7c46a45/blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for-gsk 2024-11-14T07:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/02ecfc6c06c1ffad/bergenbio-asa-fra-7bg0-q3-2024-earnings-call-highlights-yahoo-finance 2024-11-14T07:05:30+00:00 weekly 0.7 https://trial.medpath.com/news/c908099409d2095c/europe-can-learn-from-israel-s-uniquely-positioned-healthtech-ecosystem 2024-11-14T06:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/f39c46f27f2afcab/acelyrin-inc-receives-buy-rating-from-tyler-van-buren-due-to-clinical-progress-and 2024-11-14T06:05:43+00:00 weekly 0.7 https://trial.medpath.com/news/6f6d7636153a70d8/insights-from-the-spyral-htn-off-and-htn-on-med-trials-hypertension-research-nature 2024-11-14T05:57:47+00:00 weekly 0.7 https://trial.medpath.com/news/970040628f63f34f/twice-yearly-lenacapavir-injections-significantly-reduce-hiv-risk-purpose-2-trial-shows 2024-11-14T05:50:50+00:00 weekly 0.7 https://trial.medpath.com/news/7ea498c6d12f2561/alvotech-reports-financial-results-for-the-first-nine-months-of-2024-yahoo-finance 2024-11-14T05:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/a1a6707499939daf/ptc-therapeutics-announces-fda-approval-of-aadc-deficiency-gene-therapy 2024-11-14T05:03:08+00:00 weekly 0.7 https://trial.medpath.com/news/807441921fd1c1b6/polypid-reports-q3-results-amid-shield-ii-trial-progress-tipranks-com 2024-11-14T04:07:38+00:00 weekly 0.7 https://trial.medpath.com/news/6386326c8be604b9/pharvaris-reports-third-quarter-2024-financial-results-and-highlights-recent-business-updates 2024-11-14T03:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/0a425eeafff4c405/impact-of-sars-cov-2-infection-on-respiratory-and-gut-microbiome-stability-nature 2024-11-14T02:48:10+00:00 weekly 0.7 https://trial.medpath.com/news/4c8a8f0299c2a69b/immutep-positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-finance-news-network 2024-11-14T02:37:49+00:00 weekly 0.7 https://trial.medpath.com/news/db9ab56c4c4a6a0f/perceptive-eclinical-unveils-clinphone-5-next-generation-clinical-trial-management-platform 2024-11-14T01:41:26+00:00 weekly 0.7 https://trial.medpath.com/news/942d81bf133b19cd/the-il-1b-inhibitor-canakinumab-in-previously-treated-lower-risk-myelodysplastic-syndromes 2024-11-14T01:39:48+00:00 weekly 0.7 https://trial.medpath.com/news/ace2efb5e55906d0/fda-approves-danziten-nilotinib-tablets-the-first-and-only-nilotinib-with-no-mealtime-restrictions 2024-11-14T01:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/20a2117f9e4e70e9/vaccine-shows-promise-against-aggressive-breast-cancer-washu-medicine 2024-11-14T01:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/b33cbe406c6b0075/innovationrx-positive-clinical-trial-results-for-generative-ai-designed-drug-forbes 2024-11-14T00:50:56+00:00 weekly 0.7 https://trial.medpath.com/news/754230727a05d7e9/immutep-positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-finance-news-network 2024-11-14T00:45:39+00:00 weekly 0.7 https://trial.medpath.com/news/61631f31b58440ed/tirzepatide-shows-98-7-diabetes-prevention-at-3-years-drug-discovery-and-development 2024-11-14T00:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/7c390a53430f3c2d/new-therapeutic-approach-for-severe-covid-19-faster-recovery-and-reduction-in-mortality 2024-11-14T00:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/5a9d45881af9efb0/abbisko-announces-positive-results-from-phase-3-maneuver-study-of-pimicotinib-to-treat 2024-11-14T00:29:43+00:00 weekly 0.7 https://trial.medpath.com/news/5c9014b0b5d44f36/rhythm-pharmaceuticals-announces-publication-of-results-from-phase-3-study-of-morningstar 2024-11-14T00:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/15e9cffb2f15b59e/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-of-behcet-s-disease 2024-11-14T00:11:23+00:00 weekly 0.7 https://trial.medpath.com/news/5f9f1ed29997edb3/astrazeneca-daiichi-sankyo-submit-bla-to-fda-for-lung-cancer-treatment 2024-11-14T00:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/8113dda1754797ab/pila-pharma-announces-selection-of-clinical-trial-site-and-decision-to 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/52da65c132adad30/j-j-says-drug-combo-contains-lung-cancer-from-spreading-for-longer 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4dd7c9e54e59a5b8/fda-accepts-leo-pharma-s-filing-of-delgocitinib-cream-new 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4f243201e0b482cc/significant-developments-in-biosimilars-and-pharmaceuticals-in-2024 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2f9661ac8d5ae6ab/spero-therapeutics-reports-third-quarter-2024-financial-results-and-business-update 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c4c479b1881a671c/traws-pharma-provides-business-update-and-reports-q3 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f851ed92d70773c0/blood-test-for-alzheimer-s-granted-breakthrough-device-status-by-fda 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d39f83f6ab223c62/gri-bio-advances-phase-2a-trial-of-gri-0621-for-idiopathic-pulmonary-fibrosis-with-promising-interim-safety-data 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/55731d19b0afab6f/piecing-together-the-proper-btk-usage-in-cll-onclive 2024-11-13T23:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/f26ad1a4cebdc4d4/breakthrough-why-tb-drug-fights-resistant-strains-mirage-news 2024-11-13T23:40:43+00:00 weekly 0.7 https://trial.medpath.com/news/2cdd28f52d089602/nlrp3-protein-inhibitors-clinical-trial-pipeline-appears-globenewswire 2024-11-13T23:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/338df5d92d40b177/fda-grants-accelerated-approval-to-ptc-therapeutics-gene-therapy-for-aadc-deficiency 2024-11-13T23:38:02+00:00 weekly 0.7 https://trial.medpath.com/news/6ade859932094a6f/fda-approves-ptc-therapeutics-gene-therapy-upstaza-for-aadc-deficiency-cgtlive-r 2024-11-13T23:32:04+00:00 weekly 0.7 https://trial.medpath.com/news/a3b31cfb337bd770/clearpoint-neuro-makes-history-with-first-fda-approved-brain-gene-therapy-device 2024-11-13T23:20:57+00:00 weekly 0.7 https://trial.medpath.com/news/b5c5ba40412fd18c/ptc-therapeutics-announces-fda-approval-of-aadc-deficiency-gene-therapy 2024-11-13T23:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/bbff47f37b8657e9/aethlon-medical-announces-financial-results-for-the-fiscal-second-quarter-ended 2024-11-13T22:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/c9def3f010098b0f/75-key-companies-charting-new-frontiers-in-multiple-sclerosis-therapeutic-space-delveinsight 2024-11-13T22:48:31+00:00 weekly 0.7 https://trial.medpath.com/news/98c9bb73352d62f3/rbc-s-insights-on-biotech-stocks-top-investor-questions-answered 2024-11-13T22:46:34+00:00 weekly 0.7 https://trial.medpath.com/news/946fbbc52109b9ca/altimmune-s-pemvidutide-a-promising-obesity-treatment-with-strategic-phase-iii-development 2024-11-13T22:45:54+00:00 weekly 0.7 https://trial.medpath.com/news/54ded3d7f3b1907e/fda-rejects-full-approval-of-liver-disease-drug-becker-s-hospital-review 2024-11-13T22:41:54+00:00 weekly 0.7 https://trial.medpath.com/news/f915e784b83b6748/smile-stereotactic-multiple-fraction-radiotherapy-for-non-spine-bone-metastases-trials 2024-11-13T22:41:39+00:00 weekly 0.7 https://trial.medpath.com/news/f24f56b19bc416ff/no-rara-syros-trouble-mds-phase-iii-sinks-tamibarotene-bioworld 2024-11-13T22:38:37+00:00 weekly 0.7 https://trial.medpath.com/news/20aa6bc042aec6b8/a-study-of-the-efficacy-and-safety-of-kus121-in-participants-with-acute-non-arteritic-central 2024-11-13T22:19:07+00:00 weekly 0.7 https://trial.medpath.com/news/b25fedba990cad56/metsera-raises-215m-to-accelerate-obesity-drug-plans-biopharma-dive 2024-11-13T22:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/9530bb491139f638/all-in-the-blood-new-way-to-detect-drug-resistance-in-ovarian-cancer-patients-wehi 2024-11-13T22:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/449bf5a3f66ad5c2/vicarious-surgical-says-first-surgical-robot-trials-remain-on-track-massdevice 2024-11-13T22:00:14+00:00 weekly 0.7 https://trial.medpath.com/news/8df962d4830a8243/cmc-pharma-extends-shelf-life-of-medical-countermeasure-receives-fda-approval 2024-11-13T21:40:25+00:00 weekly 0.7 https://trial.medpath.com/news/c6a40c38d97aa45d/elicio-therapeutics-reports-q3-eps-1-39-consensus-73c-tipranks-com 2024-11-13T21:28:36+00:00 weekly 0.7 https://trial.medpath.com/news/ffa14f61dbf0e15b/woods-cho-awarded-76m-nih-grant-to-conduct-clinical-trials-for-youth-at-risk-for-schizophrenia 2024-11-13T21:24:26+00:00 weekly 0.7 https://trial.medpath.com/news/99108a16fc615f9b/nurexone-s-exopten-secures-ema-orphan-drug-status-for-spinal-cord-injury-treatment 2024-11-13T21:20:40+00:00 weekly 0.7 https://trial.medpath.com/news/c724cceb6933de44/diamedica-updates-remedy2-trial-timeline-reports-50-2m-cash-position-for-q3-2024 2024-11-13T21:20:33+00:00 weekly 0.7 https://trial.medpath.com/news/415478f3fcc4a5c4/elicio-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-13T21:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/3cf62fbbf449f56a/genfit-announces-corporate-updates-and-upcoming-participation-at-the-liver-meeting-r-2024 2024-11-13T21:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/11a7e87db9a9967b/nurexone-biologic-secures-ema-orphan-status-for-exopten-in-globenewswire 2024-11-13T21:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/ca39eadf9f43bf24/intensity-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-13T21:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/25e71c2fd8825362/elicio-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-13T21:13:55+00:00 weekly 0.7 https://trial.medpath.com/news/8ed08f08022a70c2/structure-therapeutics-announces-first-patients-dosed-in-phase-2b-access-clinical-study 2024-11-13T21:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/4c4c78bda37dd209/genfit-announces-corporate-updates-and-upcoming-participation-at-the-liver-meeting-r-2024 2024-11-13T21:13:23+00:00 weekly 0.7 https://trial.medpath.com/news/86d751ae6a7dc5ae/tonix-pharma-to-present-key-fibromyalgia-drug-data-awaits-fda-decision-on-fast 2024-11-13T21:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/7d3923fe301986b5/intensity-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-13T21:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/debeda0d5969f709/structure-therapeutics-launches-phase-2b-obesity-drug-trial-expands-testing-to-higher-doses 2024-11-13T21:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/94929e64e968f7fc/taysha-gene-reports-strong-safety-data-fda-approval-for-tsha-102-trials-stock-titan 2024-11-13T21:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/02bfba833351400a/immuneering-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-13T21:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/756c5e5f05e0493f/how-a-gene-agnostic-approach-opens-doors-to-new-therapeutics-ophthalmology-times-europe 2024-11-13T21:06:14+00:00 weekly 0.7 https://trial.medpath.com/news/2bf569543ff61462/syros-s-hopes-dashed-as-tamibarotene-flunks-phase-iii-mds-trial-citeline 2024-11-13T21:04:01+00:00 weekly 0.7 https://trial.medpath.com/news/d6a63d73091d2f10/novabone-receives-fda-clearance-for-expanded-indications-of-putty-in-interbody-fusion 2024-11-13T20:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/139cc90f72db44cb/fda-grants-de-novo-clearance-to-stone-clear-device-urology-times 2024-11-13T20:49:59+00:00 weekly 0.7 https://trial.medpath.com/news/e53d88b510d19a59/phaxiam-reports-third-quarter-2024-financial-information-yahoo-finance 2024-11-13T20:35:29+00:00 weekly 0.7 https://trial.medpath.com/news/6518714c722b0a4d/fda-accepts-resubmission-of-pz-cel-gene-therapy-bla-for-epidermolysis-bullosa 2024-11-13T20:33:03+00:00 weekly 0.7 https://trial.medpath.com/news/25dcb5f45d1c3111/gilead-presents-full-purpose-2-data-results-for-twice-yearly-lenacapavir-for-hiv 2024-11-13T20:30:46+00:00 weekly 0.7 https://trial.medpath.com/news/af7ec018f877409a/ethics-board-approval-granted-for-lexaria-s-12-week-phase-1b-dehydratech-glp-1-study 2024-11-13T20:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/e931d5046e066327/agenus-top-brass-sued-over-fda-response-to-cancer-drug-trial-bloomberg-law-news 2024-11-13T20:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/1a41e423b8f3316e/wint-patient-enrollment-in-seismic-c-trial-starts-patent-position-expands 2024-11-13T20:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/3dd9990cd11fb283/remdesivir-becomes-the-first-drug-for-covid-19-recommended-for-use-in-the-eu-telegrafi 2024-11-13T19:39:12+00:00 weekly 0.7 https://trial.medpath.com/news/7096255042b4291b/lundbeck-ceo-wants-to-focus-on-development-amid-rebuilding-it-really-changes-lundbeck-s-profile 2024-11-13T19:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/964ba862b82a5457/cellid-finishes-phase-3-dosing-of-omicron-targeted-covid-19-vaccine-kbr 2024-11-13T19:06:50+00:00 weekly 0.7 https://trial.medpath.com/news/f2c348fbe438d094/highlights-from-the-2024-world-conference-on-lung-cancer-the-asco-post 2024-11-13T19:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/969d1c1f0106a04d/trex-bio-raises-84m-to-compete-in-crowded-immune-drug-field-biopharma-dive 2024-11-13T19:00:38+00:00 weekly 0.7 https://trial.medpath.com/news/aca1e510aa68539a/preventing-rejection-in-pancreatic-islet-transplant-uchicago-medicine 2024-11-13T18:49:35+00:00 weekly 0.7 https://trial.medpath.com/news/37060734b9726d64/fda-approves-novel-companion-diagnostic-assay-the-asco-post 2024-11-13T18:49:28+00:00 weekly 0.7 https://trial.medpath.com/news/df131e94abbcf52d/atsena-therapeutics-and-nippon-shinyaku-enter-exclusive-license-agreement-for-atsn-101 2024-11-13T18:44:08+00:00 weekly 0.7 https://trial.medpath.com/news/10f984f4922bbebd/astrazeneca-daiichi-sankyo-seek-us-fda-s-accelerated-approval-for-datopotamab-pharmabiz 2024-11-13T18:30:10+00:00 weekly 0.7 https://trial.medpath.com/news/c5cd4e73980713ee/astrazeneca-merck-s-koselugo-shows-promise-in-adults-with-neurofibromatosis-type-1 2024-11-13T18:24:59+00:00 weekly 0.7 https://trial.medpath.com/news/0594d5a2dcf2a308/fda-expands-med-el-cochlear-implant-indications-the-hearing-review 2024-11-13T18:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/1e91b1af0ce4577b/ars-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-13T17:59:21+00:00 weekly 0.7 https://trial.medpath.com/news/a2daf8b157c9f10c/msd-and-astrazeneca-report-positive-topline-data-from-koselugo-trial-for-nf1 2024-11-13T17:53:05+00:00 weekly 0.7 https://trial.medpath.com/news/7c53e9141b0a3661/kadimastem-nls-merge-to-advance-als-therapy-astrorx-other-drugs-als-news-today 2024-11-13T17:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/469e7d44906b7982/atai-posts-26m-loss-but-progresses-on-psychedelic-clinical-trials-green-market-report 2024-11-13T17:39:33+00:00 weekly 0.7 https://trial.medpath.com/news/6a2d4bf354cfe71f/can-canada-s-psychedelic-drug-developers-shake-off-the-sector-s-bad-trip 2024-11-13T17:32:52+00:00 weekly 0.7 https://trial.medpath.com/news/cb2caae23188d0d1/x4-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-13T17:31:17+00:00 weekly 0.7 https://trial.medpath.com/news/c3eaafdd7af0a4af/fda-clears-outpatient-cardiac-telemetry-for-smartcardia-ecg-patch-massdevice 2024-11-13T17:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/6d603f6cf80642b5/new-data-on-pst-611-from-pulsesight-therapeutics-sas-shared-at-ever-congress-2024 2024-11-13T17:23:28+00:00 weekly 0.7 https://trial.medpath.com/news/9c4dfe9a26e9eb41/koselugo-demonstrates-clinically-meaningful-improvement-in-adults-with-symptomatic 2024-11-13T17:17:50+00:00 weekly 0.7 https://trial.medpath.com/news/0857a2ee8e82b6b6/kezar-struck-again-with-second-fda-hold-clinical-trials-arena 2024-11-13T17:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/bc8c8da6e0bf6a7c/syndax-s-stock-sinks-by-25-despite-aml-trial-meeting-primary-endpoint 2024-11-13T17:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/c610dc5e6e70aeb8/momelotinib-wins-canadian-approval-for-myelofibrosis-with-anemia-onclive 2024-11-13T17:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/ec12085e363581fb/ge-healthcare-receives-fda-clearance-for-head-only-signa-magnus-3-0t-mri-system 2024-11-13T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/b64ea9b1a869f931/sonomotion-announces-fda-de-novo-clearance-for-its-stone-cleartm-device 2024-11-13T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/fd8f4fb2e19d0a31/pimicotinib-significantly-improves-responses-vs-placebo-in-tgct-cancer-network 2024-11-13T17:06:05+00:00 weekly 0.7 https://trial.medpath.com/news/c9eeb7f1a3e67373/phaxiam-reports-third-quarter-2024-financial-information-stock-titan 2024-11-13T17:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/0ae9712b925208a5/valneva-and-limmatech-announce-first-vaccination-in-phase-2b-human-challenge-study 2024-11-13T16:48:43+00:00 weekly 0.7 https://trial.medpath.com/news/ca9b9ca5a9e9f2cd/lenacapavir-for-prep-demonstrates-strong-efficacy-adherence-in-phase-3-trial 2024-11-13T16:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/6cd07a4b1aceacd5/phaxiam-reports-third-quarter-2024-financial-information-globenewswire 2024-11-13T16:47:20+00:00 weekly 0.7 https://trial.medpath.com/news/947515e505fb96c5/fda-rejects-full-approval-of-ocaliva-as-second-line-pbc-treatment-liver-disease-news 2024-11-13T16:42:24+00:00 weekly 0.7 https://trial.medpath.com/news/311d6829e54e09dd/boehringer-ingelheim-and-mtm-vision-join-forces-to-combat-vision-loss-from-diabetes 2024-11-13T16:29:39+00:00 weekly 0.7 https://trial.medpath.com/news/3d394d483279ff46/livanova-hits-goals-in-sleep-apnea-implant-trial-plans-fda-filing-medtech-dive 2024-11-13T16:26:25+00:00 weekly 0.7 https://trial.medpath.com/news/dcb318a54133e9a4/chlorhexidine-alcohol-compared-with-povidone-iodine-alcohol-skin-antisepsis-protocols-in 2024-11-13T16:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/f8e320459069c4e0/amgen-shares-sink-on-obesity-drug-concerns-astrazeneca-to-spend-3-5b-on-manufacturing 2024-11-13T16:22:11+00:00 weekly 0.7 https://trial.medpath.com/news/012757d0e1ba1ce1/recce-pharmaceuticals-receives-approval-for-phase-iii-dfi-trial-in-indonesia 2024-11-13T16:20:08+00:00 weekly 0.7 https://trial.medpath.com/news/1233f31d9b1493dc/improving-atopic-dermatitis-treatment-for-adolescents-feinberg-news-center 2024-11-13T16:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/a07e208ce9f8dee2/regeneron-sanofi-s-dupixent-approval-signals-major-treatment-breakthrough-for-smokers 2024-11-13T16:12:59+00:00 weekly 0.7 https://trial.medpath.com/news/e30f3b9f56221eaa/ozempic-may-help-curb-alcohol-addiction-study-suggests 2024-11-13T16:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/64b326d2bb8642a5/targeted-magnetic-stimulation-slows-alzheimer-s-progression-in-phase-ii-study 2024-11-13T16:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/8b22d58218fb4124/recce-pharmaceuticals-receives-approval-for-phase-iii-dfi-trial-in-indonesia 2024-11-13T16:05:06+00:00 weekly 0.7 https://trial.medpath.com/news/3aa14dc7c005e049/cell-therapy-fights-lethal-childhood-brain-cancer-in-stanford-medicine-trial-news-center 2024-11-13T16:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/57253b5f41ba9a69/intercept-loses-ocaliva-fda-full-approval-bid-in-rare-liver-disease 2024-11-13T15:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/6937d6bc1912bad4/non-cystic-fibrosis-bronchiectasis-pipeline-insight-over-globenewswire 2024-11-13T15:38:07+00:00 weekly 0.7 https://trial.medpath.com/news/09ba6f3dc055487d/minoryx-ceo-marc-martinell-discusses-a-new-small-molecule-therapeutic-for-ald 2024-11-13T15:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/76bee0569ba38499/komet-phase-iii-trial-of-koselugo-shows-statistically-significant-and-clinically-meaningful 2024-11-13T15:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/e08da927b9d61fbe/vergent-bioscience-completes-enrollment-in-phase-2-visualize-trial-evaluating-potential 2024-11-13T15:21:01+00:00 weekly 0.7 https://trial.medpath.com/news/2a22189ec115a4ce/trace-neuroscience-launches-with-101m-and-a-potential-genomic-als-target 2024-11-13T15:20:03+00:00 weekly 0.7 https://trial.medpath.com/news/2f3c1ec1dab1ad4a/asha-therapeutics-awarded-barnett-drug-development-grant-by-the-als-association-to 2024-11-13T15:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/6aaa3783c9080071/inmune-bio-inc-announces-final-enrollment-of-208-patients-in-phase-2-trial-in-early 2024-11-13T15:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/b6168405e20f53b0/precision-medicine-in-nsclc-the-power-of-molecular-testing-cancer-network 2024-11-13T15:06:18+00:00 weekly 0.7 https://trial.medpath.com/news/689d3269113ce09d/health-canada-approves-gsk-s-ojjaara-for-myelofibrosis-in-anaemia-patients 2024-11-13T15:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/61f9aa98ede13d13/induction-of-cure-in-early-arthritis-i-cea-study-protocol-for-an-investigator-initiated-trials 2024-11-13T14:38:46+00:00 weekly 0.7 https://trial.medpath.com/news/18d825675e1d58ac/asha-therapeutics-secures-als-grant-for-breakthrough-sarm1-drug-development 2024-11-13T14:36:43+00:00 weekly 0.7 https://trial.medpath.com/news/e04758a8512ecbde/lexaria-s-dehydratech-diabetes-study-advances-fda-track-phase-1b-trial-gets-key-approval 2024-11-13T14:36:41+00:00 weekly 0.7 https://trial.medpath.com/news/782a616b2e34a2f5/rejuvenating-lung-stem-cells-for-idiopathic-pulmonary-fibrosis-drug-discovery-news 2024-11-13T14:24:08+00:00 weekly 0.7 https://trial.medpath.com/news/d1902c747a3b5f7d/atai-life-sciences-advances-therapeutic-pipeline-in-q3-with-fda-approval-of-vls-01 2024-11-13T14:22:30+00:00 weekly 0.7 https://trial.medpath.com/news/710f77eb9ef7ca35/inmune-bio-hits-major-milestone-208-patients-enrolled-in-phase-2-alzheimer-s-trial 2024-11-13T14:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/20d9e8e0b0fca72a/med-el-corporation-announces-fda-approval-of-expanded-candidacy-indications-morningstar 2024-11-13T14:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/d63b33a1118c79ca/helix-debuts-novel-precision-effectiveness-model-that-predicts-12-month-weight-loss 2024-11-13T14:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/232df18795feea61/inmune-bio-inc-announces-final-enrollment-of-208-patients-globenewswire 2024-11-13T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/news/a889feea9a337500/gemvax-kael-announces-results-from-phase-2a-clinical-trial-for-psp-aftd 2024-11-13T14:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/91e487fd9612b8d6/ge-healthcare-gets-fda-approval-for-head-only-mri-scanner-morningstar 2024-11-13T13:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/bf4b66b4dfe65754/intelligent-bio-solutions-hits-major-breakthrough-in-drug-detection-study-fda-filing-next 2024-11-13T13:38:22+00:00 weekly 0.7 https://trial.medpath.com/news/8e74775959b1603e/syros-stock-craters-after-lead-cancer-therapy-flops-in-phase-iii-trial-yahoo-finance 2024-11-13T13:32:41+00:00 weekly 0.7 https://trial.medpath.com/news/646ca370167ebe35/ibi354-shows-efficacy-and-safety-in-her2-and-her2-low-advanced-breast-cancer 2024-11-13T13:27:58+00:00 weekly 0.7 https://trial.medpath.com/news/2f42ee4abfa6af80/longboard-commences-phase-iii-trial-of-bexicaserin-for-dees-seizure-treatment 2024-11-13T13:24:18+00:00 weekly 0.7 https://trial.medpath.com/news/9a8713c2d14adbf0/biorestorative-therapies-inc-reports-positive-preliminary-phase-2-brtx-100-clinical-data 2024-11-13T13:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/bc5a1716b7335477/cardiol-therapeutics-inc-added-to-prism-emerging-biotech-index-globenewswire 2024-11-13T13:15:50+00:00 weekly 0.7 https://trial.medpath.com/news/f89824498e160b93/inovio-s-ino-3107-shows-breakthrough-immune-response-in-rrp-treatment-trial 2024-11-13T13:15:06+00:00 weekly 0.7 https://trial.medpath.com/news/7d9837d27e5f0c03/moonlake-immunotherapeutics-starts-phase-3-izar-program-of-globenewswire 2024-11-13T13:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/d58bba9ca7a95940/med-el-corporation-announces-fda-approval-of-expanded-candidacy-indications-and 2024-11-13T13:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/970e60d4e6c239ce/enveda-announces-first-candidate-discovered-from-nature-using-ai-advances-to-clinical-trials 2024-11-13T13:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/23d163cf2400a328/smartcardia-receives-fda-clearance-for-outpatient-cardiac-telemetry-for-its-7-lead-ecg 2024-11-13T13:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/c9a42b55fe4a5ca0/shilpa-medicare-s-acceptance-by-usfda-of-nda-filed-by-its-cdmo-partner-unicycive-for 2024-11-13T12:55:44+00:00 weekly 0.7 https://trial.medpath.com/news/6a7b9f1bf998f1eb/cybin-initiates-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for 2024-11-13T12:50:24+00:00 weekly 0.7 https://trial.medpath.com/news/549ceebb7ba41863/mural-oncology-announces-third-quarter-2024-financial-results-and-provides-update-on 2024-11-13T12:41:11+00:00 weekly 0.7 https://trial.medpath.com/news/f0fa67e485cd75f5/cybin-initiates-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for 2024-11-13T12:40:49+00:00 weekly 0.7 https://trial.medpath.com/news/72468520838af905/jeremie-calais-md-highlights-study-of-psma-pet-vs-bone-scan-in-metastatic-prostate-cancer 2024-11-13T12:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/1d1432ceba53a678/j-j-s-nipocalimab-granted-fda-breakthrough-designation-for-sjogren-s-disease-pmlive 2024-11-13T12:24:55+00:00 weekly 0.7 https://trial.medpath.com/news/8dadac2cbd0cc490/unicycive-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-13T12:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/e0188661f866770e/polypid-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-13T12:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/20db9e970d2dfa0b/leap-therapeutics-reports-third-quarter-2024-financial-results-stock-titan 2024-11-13T12:12:18+00:00 weekly 0.7 https://trial.medpath.com/news/3c5747877f1a6067/longboard-commences-phase-iii-trial-of-bexicaserin-for-dees-seizure-treatment 2024-11-13T12:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/86d29866fe5cbc5f/syros-stock-craters-after-lead-cancer-therapy-flops-in-phase-iii-trial 2024-11-13T11:53:09+00:00 weekly 0.7 https://trial.medpath.com/news/589d69e393040f97/x4-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-13T11:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/1d071bc6ec025a3b/immunic-announces-publication-of-data-from-phase-1-1b-clinical-trial-of-imu-856-pr-newswire 2024-11-13T11:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/fd4f780f3b795c56/gyre-therapeutics-reports-third-quarter-2024-and-year-to-date-financial-results-and 2024-11-13T11:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/a1008db780bc3f99/gyre-therapeutics-reports-third-quarter-2024-and-globenewswire 2024-11-13T11:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/d6c232fce039047b/genascence-granted-fda-fast-track-designation-for-gnsc-001-in-patients-with-biospace 2024-11-13T11:01:32+00:00 weekly 0.7 https://trial.medpath.com/news/ccbd56e30acb1797/j-j-seek-approval-for-first-drug-to-treat-high-risk-smoldering-myeloma-pharmafile 2024-11-13T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/news/5a9bc011e2e80c91/azitra-inc-announces-q3-2024-financial-results-and-provides-business-updates 2024-11-13T10:21:15+00:00 weekly 0.7 https://trial.medpath.com/news/d1048515a6e87a9c/amgen-provides-statement-on-maritide-phase-1-data 2024-11-13T10:20:23+00:00 weekly 0.7 https://trial.medpath.com/news/2d73356ac8138764/immuneonco-advances-cancer-drug-trials-with-promising-results-tipranks-com 2024-11-13T10:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/de45b1ff9edfabab/menin-suits-syndax-s-revumenib-phase-ii-win-in-aml-measured-bioworld 2024-11-13T09:57:58+00:00 weekly 0.7 https://trial.medpath.com/news/c3567379504282e6/mediprint-ophthalmics-reveals-positive-results-from-phase-2b-study-of-ll-bmt1-contact-lens 2024-11-13T09:55:41+00:00 weekly 0.7 https://trial.medpath.com/news/2f31f0076bd737a2/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-formulation 2024-11-13T09:39:12+00:00 weekly 0.7 https://trial.medpath.com/news/05e2f3aafe9745d9/curateq-biologics-gains-ema-gmp-certification-for-biosimilars-facility 2024-11-13T09:33:32+00:00 weekly 0.7 https://trial.medpath.com/news/cc5c4b61e6bcfc1f/astrazenecas-contribution-to-the-breast-cancer-market-precedence-research 2024-11-13T09:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/516671b57c66825e/topical-drug-combos-may-be-beneficial-for-cipn-oncology-nursing-news 2024-11-13T09:06:24+00:00 weekly 0.7 https://trial.medpath.com/news/2150096b48b12ff8/microbiotica-doses-first-patient-in-phase-1b-trial-of-mb310-precision-microbiome-therapy-for-ulcerative-colitis 2024-11-13T09:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/e5e93b4daf22fa77/global-pharma-s-investment-in-korean-clinical-research-grew-7-in-2023-krpia-kbr 2024-11-13T08:33:43+00:00 weekly 0.7 https://trial.medpath.com/news/7b9a89cdd2fbd125/us-fda-grants-breakthrough-therapy-designation-to-johnson-johnson-s-nipocalimab-to 2024-11-13T08:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/59d402f06f5bc176/us-fda-clears-investigational-new-drug-application-for-crispr-cas13-rna-editing-therapy 2024-11-13T08:21:45+00:00 weekly 0.7 https://trial.medpath.com/news/3502e0c67902d899/immunotherapy-drug-pembrolizumab-improves-outcomes-for-patients-with-soft-tissue-sarcoma 2024-11-13T08:20:01+00:00 weekly 0.7 https://trial.medpath.com/news/c90fab63be7b60f8/lyophilization-drives-15-annual-growth-in-novel-drug-approvals-reshaping-pharmaceutical-manufacturing 2024-11-13T08:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/d3ed8da146257ede/glucose-responsive-insulin-for-diabetes-nature-biotechnology 2024-11-13T07:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/d897038ae12d5343/pimicotinib-significantly-improved-outcomes-for-patients-with-tenosynovial-giant-cell 2024-11-13T06:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/4561d9a16875ca29/myriad-genetics-expands-prenatal-testing-access-with-retail-launch-of-sneakpeek-early-fetal-sex-test 2024-11-13T06:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/d1a488a81ddce7fa/moleculin-receives-institutional-review-board-approval-for-miracle-phase-3-pivotal-trial 2024-11-13T05:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/5311241cf9b91c80/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-13T05:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/f5a7e06818fcb3ac/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-13T05:38:16+00:00 weekly 0.7 https://trial.medpath.com/news/bbebc37b1374988d/arch-biopartners-doses-first-patient-in-canada-for-phase-ii-trial-of-lsalt-peptide-to-treat 2024-11-13T05:31:11+00:00 weekly 0.7 https://trial.medpath.com/news/8f7d07c20748e0a8/regulator-defends-new-drug-approval-fee-hike-plans-faster-review-process-kbr 2024-11-13T05:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/a89d57f9ad966708/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine 2024-11-13T04:59:07+00:00 weekly 0.7 https://trial.medpath.com/news/9d1586fb00acaa5b/revumenib-shows-promise-in-aml-trial-phase-2-results-investing-com 2024-11-13T04:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/642908e1b2aec86c/novavax-resumes-phase-3-vaccine-trials-after-fda-hold-tipranks-com 2024-11-13T04:50:25+00:00 weekly 0.7 https://trial.medpath.com/news/2de46f2021a406de/spinal-cord-injury-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-11-13T04:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/3b5b6f7ea33239da/advancements-in-tenosynovial-giant-cell-tumors-clinical-trials-highlighted-for-2024 2024-11-13T04:37:52+00:00 weekly 0.7 https://trial.medpath.com/news/6303fc3a23e02a64/sanofi-regeneron-pharmaceuticals-dupixent-approval-marks-a-significant-shift-pr-newswire 2024-11-13T04:32:02+00:00 weekly 0.7 https://trial.medpath.com/news/6223aa4444b8b5af/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results 2024-11-13T04:19:37+00:00 weekly 0.7 https://trial.medpath.com/news/cf3a1a9e8f994010/advancements-in-traumatic-brain-injury-clinical-trials-highlighted-for-2024 2024-11-13T04:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/ce2380dde4633084/china-s-anti-espionage-law-threatens-global-pharmaceutical-supply-chain-security 2024-11-13T04:06:33+00:00 weekly 0.7 https://trial.medpath.com/news/d7edb854a72b0181/zevra-therapeutics-reports-third-quarter-2024-financial-results-and-corporate-updates 2024-11-13T03:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/dc11be9267d89ec3/nxera-pharma-s-partner-centessa-initiates-phase-2-trial-with-orx750-a-novel-orexin 2024-11-13T03:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/df9f2776c59d9484/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-formulation 2024-11-13T03:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/459c1b75a2a354c7/safety-reporting-in-trials-on-glaucoma-interventions-registered-in-clinicaltrials-gov-and 2024-11-13T03:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/4cc4443b695f823d/regulator-and-funder-fda-s-orphan-products-grants-program-awards-significant-funding 2024-11-13T02:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/57c5d0fbe1fa7140/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-pr-newswire 2024-11-13T02:50:28+00:00 weekly 0.7 https://trial.medpath.com/news/8e2719218dea0cac/fda-approves-kebilidi-eladocagene-exuparvovec-tneq-gene-therapy-for-the-treatment-of-aadc-deficiency 2024-11-13T02:11:31+00:00 weekly 0.7 https://trial.medpath.com/news/f65cbb55126faac4/nivolumab-chemotherapy-combo-boosts-pfs-in-chl-poised-for-standard-use 2024-11-13T02:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/6b324e2ae55fa77c/earnings-call-legend-biotech-sees-robust-growth-in-carvykti-sales-investing-com 2024-11-13T01:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/27c3eaaad288fc0e/elraglusib-gains-fda-rare-pediatric-disease-designation-in-ewing-sarcoma 2024-11-13T01:09:15+00:00 weekly 0.7 https://trial.medpath.com/news/2f5e2d27d731460e/a-scrap-of-data-on-amgen-s-obesity-drug-maritide-wipes-out-12b-in-market-value-stat-news 2024-11-13T01:03:08+00:00 weekly 0.7 https://trial.medpath.com/news/1433fff787612637/fda-approves-the-first-flu-vaccine-for-at-home-use-providing-a-needle-free-option-mondaq 2024-11-13T00:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/ea3329ee9da4d02c/pfizer-explores-sale-of-hospital-drugs-unit-amid-strategic-restructuring 2024-11-13T00:36:50+00:00 weekly 0.7 https://trial.medpath.com/news/5c5d64cda8ff8bce/lung-cancer-takes-big-beating-from-tiny-nano-particles-synbiobeta 2024-11-13T00:21:09+00:00 weekly 0.7 https://trial.medpath.com/news/fa0349dfaa4b4847/comparison-of-drug-eluting-bead-transarterial-chemoembolization-combined-with-apatinib-nature 2024-11-13T00:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/f038e7f21f0a1466/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash 2024-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d9c067f3963a632/acurx-pharma-q3-new-patent-win-trial-progress-despite-cash-decline 2024-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/262433b6d5e8ea62/acumen-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-11-12T23:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/175363ad237b5a18/a-revolution-in-antibody-therapy-q-a-with-randy-noelle-phd-geisel-news 2024-11-12T23:50:21+00:00 weekly 0.7 https://trial.medpath.com/news/4c94f6c2b0131422/pivotal-clinical-trial-of-descartes-08-for-mg-may-start-in-2025-myasthenia-gravis-news 2024-11-12T23:40:13+00:00 weekly 0.7 https://trial.medpath.com/news/fa23c707699c5ab2/huidagene-therapeutics-ind-application-for-hg202-for-the-treatment-of-namd-cleared-by-fda 2024-11-12T23:35:31+00:00 weekly 0.7 https://trial.medpath.com/news/79a33fc4c8923a48/clinical-validation-and-real-world-impact-of-precivityad2-test-for-alzheimer-diagnosis 2024-11-12T23:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/89279183f4551e1e/repare-therapeutics-announces-agreement-with-the-us-national-cancer-institute-to 2024-11-12T23:29:40+00:00 weekly 0.7 https://trial.medpath.com/news/2049e30563acb1af/eupraxia-s-eoe-drug-shows-breakthrough-results-complete-remission-in-latest-trial-data 2024-11-12T23:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/9ce44a49beb805a2/fda-sets-pfuda-date-accepts-bla-submission-for-pz-cel-in-epidermolysis-bullosa 2024-11-12T23:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/0dec5e3707de58db/fox-chase-cancer-center-s-dr-vanessa-wookey-presents-rectal-cancer-research-at-24th 2024-11-12T23:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/a6c7f26335df975d/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T23:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/dc6b5f42cd496317/rare-disease-clinical-trials-face-logistical-challenges-experts-to-address-solutions-at-brussels-conference 2024-11-12T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5e2e2b09a72c9585/fda-receives-new-bla-for-dato-dxd-in-pretreated-egfr-advanced-nsclc-onclive 2024-11-12T22:44:08+00:00 weekly 0.7 https://trial.medpath.com/news/fe177a9fbdec4833/selumetinib-boosts-orr-in-nf1-with-inoperable-plexiform-neurofibroma-onclive 2024-11-12T22:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/b5c783327b6a175c/fda-rejects-full-approval-of-liver-disease-drug-medpage-today 2024-11-12T22:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/891ed1d2ea45a991/aura-biosciences-inc-sec-10-q-report-tradingview 2024-11-12T22:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/b6ba8dec7e44f201/azitra-inc-announces-q3-2024-financial-results-and-provides-business-updates 2024-11-12T22:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/2d3d67f7d7cbea8a/3-things-to-know-about-cobenfy-the-new-schizophrenia-drug-yale-medicine 2024-11-12T22:13:53+00:00 weekly 0.7 https://trial.medpath.com/news/334e2562a1251670/new-treatment-combination-improves-outcomes-for-small-cell-bladder-and-prostate-cancer-patients 2024-11-12T22:10:09+00:00 weekly 0.7 https://trial.medpath.com/news/530bbd4f1a1da554/gene-therapy-cap-002-gains-fda-orphan-drug-designation-for-stxbp1-developmental 2024-11-12T22:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/7842d3f99c5cc38c/eyenovia-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-12T21:46:32+00:00 weekly 0.7 https://trial.medpath.com/news/57751ca3e73db7c5/new-blood-test-detects-early-lung-damage-in-cancer-patients-on-targeted-therapy 2024-11-12T21:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/3d8e8d72051cfe8b/collaboration-to-support-phase-3-secure-trial-of-67cu-sar-bispsma-urology-times 2024-11-12T21:36:01+00:00 weekly 0.7 https://trial.medpath.com/news/4469ee08692bd84c/lisata-therapeutics-advances-clinical-trials-in-q3-ahead-of-data-rich-2025-nasdaq-lsta 2024-11-12T21:32:47+00:00 weekly 0.7 https://trial.medpath.com/news/fc913cd6a169a54a/crinetics-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-12T21:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/fb1aede80599c6cc/oncocyte-reports-commercial-launch-progress-on-track-to-sign-20-transplant-centers-by 2024-11-12T21:29:02+00:00 weekly 0.7 https://trial.medpath.com/news/c81bb79a6631f24a/fda-clears-ai-powered-breast-cancer-detection-tech-from-icad-massdevice 2024-11-12T21:22:06+00:00 weekly 0.7 https://trial.medpath.com/news/4cef406799f31eda/jenavalve-to-begin-trilogy-heart-valve-trial-massdevice 2024-11-12T21:22:05+00:00 weekly 0.7 https://trial.medpath.com/news/7b4b49a0e39aeccd/zevra-therapeutics-reports-third-quarter-2024-financial-globenewswire 2024-11-12T21:18:08+00:00 weekly 0.7 https://trial.medpath.com/news/a12f94900dc52e3a/perspective-therapeutics-reports-267-8m-cash-position-advances-cancer-drug-trials 2024-11-12T21:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/2fe13d7eab933cd0/longeveron-r-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-12T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/47e2e00e6901e6b6/artiva-biotherapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlights 2024-11-12T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/cb1ecfe001897130/aura-biosciences-reports-third-quarter-2024-financial-results-and-business-highlights 2024-11-12T21:17:48+00:00 weekly 0.7 https://trial.medpath.com/news/8b306bb487d028ca/fda-approves-renewal-for-canine-chemotherapy-induced-diarrhea-treatment 2024-11-12T21:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/be041efa6076b559/automatic-segmentation-based-multi-modal-radiomics-analysis-of-us-and-mri-for-predicting 2024-11-12T21:11:57+00:00 weekly 0.7 https://trial.medpath.com/news/d7077b77d0bd7e1b/journey-medical-corporation-reports-third-quarter-2024-globenewswire 2024-11-12T21:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/9852cdf4af11327d/perspective-therapeutics-provides-recent-business-highlights-and-reports-fiscal-3q-2024-results 2024-11-12T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/123092b6824a1706/corvus-pharmaceuticals-provides-business-update-and-reports-third-quarter-2024-stock-titan 2024-11-12T21:06:52+00:00 weekly 0.7 https://trial.medpath.com/news/fb4769a4897bbd8f/inflammatix-begins-trial-evaluating-mrna-test-for-patient-infection-status 2024-11-12T21:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/718558c4de74e967/biohaven-announces-third-quarter-2024-financial-results-and-business-developments 2024-11-12T21:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/8eae321978eeeabc/ucl-spinout-autolus-gains-us-approval-for-cancer-therapy 2024-11-12T20:58:54+00:00 weekly 0.7 https://trial.medpath.com/news/a0ed8ffb279fd47e/dyne-therapeutics-reports-third-quarter-2024-financial-results-and-corporate-update 2024-11-12T20:53:35+00:00 weekly 0.7 https://trial.medpath.com/news/02d112d65498e0b4/milestone-pharmaceuticals-reports-third-quarter-2024-globenewswire 2024-11-12T20:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/4a686e644acb9260/abeona-therapeutics-announces-fda-acceptance-of-bla-resubmission-of-pz-cel-for-the-treatment-of-recessive-dystrophic-epidermolysis-bullosa 2024-11-12T20:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/d709f2f17abd48ce/astrazeneca-announces-koselugo-met-primary-endpoing-in-komet-phase-iii-trial 2024-11-12T20:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/9b565ed91d9ae4db/insilico-plans-pivotal-trial-for-ai-based-ipf-candidate 2024-11-12T20:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/ca926787c5025a64/new-study-suggests-weight-loss-drugs-like-ozempic-could-help-with-knee-pain-here-s-why 2024-11-12T19:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/5fbca53ba736806a/syndax-announces-positive-pivotal-topline-results-from-relapsed-or-refractory-mnpm1-aml-cohort-in-augment-101-trial-of-revumenib 2024-11-12T19:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/0366398a8f6b0ff8/drug-for-infertility-puberty-disorders-hot-flashes-soon-us-scientist-times-of-india 2024-11-12T19:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/3971a4cd46928551/abbisko-s-pimicotinib-meets-endpoints-in-phase-iii-bioworld 2024-11-12T19:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/5e89af9ba621ef93/abbvie-s-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio 2024-11-12T19:03:33+00:00 weekly 0.7 https://trial.medpath.com/news/bd6944cd0210850a/astrazeneca-daiichi-sankyo-submit-biologics-license-application-of-datopotamab 2024-11-12T18:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/c6f4c68741b30b54/johnson-johnson-wins-fda-ide-for-ottava-surgical-robot-massdevice 2024-11-12T18:50:02+00:00 weekly 0.7 https://trial.medpath.com/news/126c27bf328a84d1/first-ever-randomized-clinical-trial-uses-telehealth-for-suicide-prevention-eurekalert 2024-11-12T18:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/f313907f4fd416ed/gan-lee-pharmaceuticals-announced-positive-phase-1-results-for-its-oral-glp-yahoo-finance 2024-11-12T18:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/a00f69f0ce19c2a6/prokidney-reports-third-quarter-2024-financial-results-globenewswire 2024-11-12T18:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/552c68a39d7d0c6c/fda-approves-autolus-aucatzyl-for-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia 2024-11-12T18:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/cc03f7f6a8ac6705/first-ever-randomized-clinical-trial-uses-telehealth-for-suicide-prevention-ohio-state-medical-center 2024-11-12T18:20:32+00:00 weekly 0.7 https://trial.medpath.com/news/5260e6ab26867712/protara-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T18:16:01+00:00 weekly 0.7 https://trial.medpath.com/news/1dbf8391f0d42ce6/scholar-rock-holding-corp-sec-10-q-report-tradingview 2024-11-12T18:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/69ab9793baf98297/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer 2024-11-12T18:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/47fc506f123a5f4f/actuate-announces-fda-rare-pediatric-disease-designation-granted-to-elraglusib-for-treatment-of-ewing-sarcoma 2024-11-12T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/77757faa1717303b/fda-denies-ocaliva-full-approval-in-primary-biliary-cholangitis-safety-data-still-in-play 2024-11-12T18:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/7599034c23c22901/indaptus-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T18:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/de27c1a6c37e9cd2/naim-alkhouri-md-first-real-world-data-for-resmetirom-use-in-clinical-practice-hcplive 2024-11-12T18:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/c0dc3998f5307972/revumenib-for-npm1-mutant-aml-succeeds-in-pivotal-trial-targeted-oncology 2024-11-12T18:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/80c619b17ade523e/key-clinical-compound-updates-from-october-2024 2024-11-12T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8979456e3ec29759/cancer-cases-in-bluebird-s-gene-therapy-trials-nature-biotechnology 2024-11-12T17:41:20+00:00 weekly 0.7 https://trial.medpath.com/news/668c913cccf5892d/novel-ai-procured-ism001-055-demonstrates-great-promise-for-treatment-of-ipf 2024-11-12T17:36:25+00:00 weekly 0.7 https://trial.medpath.com/news/07c0811f390b6254/cerevance-reports-results-from-trial-of-cvn293-for-neurodegenerative-conditions 2024-11-12T17:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/fccb99909b78792e/fda-lifts-clinical-hold-on-combined-covid-19-influenza-vaccine-trials 2024-11-12T17:32:54+00:00 weekly 0.7 https://trial.medpath.com/news/da67476371e5211f/springworks-therapeutics-reports-third-quarter-2024-globenewswire 2024-11-12T17:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/22c439acb3c4df05/abbisko-s-pimicotinib-hits-primary-endpoint-in-phase-3-tgct-trial 2024-11-12T17:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/fe93b053ebe96071/eu-crunch-time-for-kizfizo-sipavibart-coacillium-eight-other-products 2024-11-12T17:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/a2fb0aa92f30463b/qnrx-international-sites-participating-in-qrx003-ns-study-zacks-small-cap-research 2024-11-12T17:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/990de5bc9223a1aa/23andme-cuts-40-of-its-workforce-and-discontinues-therapeutics-division-abc-news 2024-11-12T17:28:22+00:00 weekly 0.7 https://trial.medpath.com/news/e317bfddc047a450/j-j-s-ottava-surgical-robot-to-begin-clinical-trial-after-fda-nod-medtech-dive 2024-11-12T17:27:59+00:00 weekly 0.7 https://trial.medpath.com/news/1c1493665c3b9e72/pimicotinib-meets-orr-end-point-in-tenosynovial-giant-cell-tumor-onclive 2024-11-12T17:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/d125c2e5e1582633/a-framework-for-n-of-1-trials-of-individualized-gene-targeted-therapies-for-genetic-diseases 2024-11-12T17:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/647d693335a6d1a2/neurogene-hits-a-setback-in-the-clinic-days-after-fundraise-biopharma-dive 2024-11-12T17:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/123397ab81c01636/medidata-and-bioforum-bolster-decade-long-relationship-to-advance-clinical-data-and 2024-11-12T17:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/03cb191b5ba0e0dc/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine 2024-11-12T17:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/5926dee4845d1fd6/entinostat-in-combination-with-nivolumab-in-metastatic-pancreatic-ductal-adenocarcinoma 2024-11-12T17:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/e1a3fdb58fbc8bd3/uf-health-study-to-assess-pharmacogenetic-testing-in-the-er 2024-11-12T17:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/e3825eac633e1b83/immuno-cure-biotech-presents-promising-results-on-phase-i-clinical-trial-of-a-therapeutic 2024-11-12T17:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/f9ed99b8d488574a/casting-a-wide-net-when-is-the-optimal-time-for-177lu-dotatate-treatment 2024-11-12T17:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/9829869a608c6f38/fda-receives-new-bla-for-dato-dxd-in-advanced-egfr-nsclc-cancer-network 2024-11-12T17:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/5da3524fd674eb03/fda-accepts-bla-resubmission-for-epidermolysis-bullosa-gene-therapy-drug-topics 2024-11-12T16:52:38+00:00 weekly 0.7 https://trial.medpath.com/news/ed07846556ceb41f/biotech-investors-including-third-rock-pump-100m-into-a-startup-s-genetic-medicine-for-als 2024-11-12T16:51:53+00:00 weekly 0.7 https://trial.medpath.com/news/72444763062658d8/boston-scientific-resumes-pfa-trial-in-new-patient-group-after-pausing-enrollment 2024-11-12T16:45:56+00:00 weekly 0.7 https://trial.medpath.com/news/3e9251e9e9bde228/fda-grants-breakthrough-therapy-designation-to-nipocalimab-for-sjogren-s-disease-healio 2024-11-12T16:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/1e6d20202cc67cd3/fda-accepts-new-drug-application-for-donidalorsen-healio 2024-11-12T16:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/68f2f2de1348f138/dmts-are-major-clinical-research-focus-for-parkinson-s-disease-analysis-shows 2024-11-12T16:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/10ca7380a1f7c8d5/astrazeneca-daiichi-revise-approval-plans-for-enhertu-successor-biopharma-dive 2024-11-12T16:26:24+00:00 weekly 0.7 https://trial.medpath.com/news/9db4073b99a0d2f2/sareum-holdings-edison-vox-markets 2024-11-12T16:20:07+00:00 weekly 0.7 https://trial.medpath.com/news/925af22b8f20d634/formation-bio-collaborates-with-openai-and-sanofi-to-introduce-muse-marketscreener 2024-11-12T16:16:57+00:00 weekly 0.7 https://trial.medpath.com/news/c36f19839d12dea0/one-genomic-test-can-diagnose-nearly-any-infection-uc-san-francisco 2024-11-12T16:04:43+00:00 weekly 0.7 https://trial.medpath.com/news/98e01326597c9b84/peta-the-oncostory-that-started-when-he-was-four-months-old-the-university-hospital-brno 2024-11-12T15:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/603fd9dd83b73b65/medidata-and-bioforum-bolster-decade-long-relationship-to-advance-clinical-data-and 2024-11-12T15:57:18+00:00 weekly 0.7 https://trial.medpath.com/news/62e798bd832f8b6d/j-j-fda-green-light-for-robotic-system-trial-marketscreener 2024-11-12T15:56:27+00:00 weekly 0.7 https://trial.medpath.com/news/18866b999aaa80b0/nevro-wins-ce-mark-for-hfx-iq-spinal-cord-stim-for-pain-relief-massdevice 2024-11-12T15:53:18+00:00 weekly 0.7 https://trial.medpath.com/news/f64d0eb18c977ea2/magstim-earns-fda-clearance-for-transcranial-magnetic-stimulation-that-treats-depression-ocd 2024-11-12T15:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/4a9ba70a483e0ecb/fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combo-vaccine 2024-11-12T15:37:30+00:00 weekly 0.7 https://trial.medpath.com/news/0e79c1a3fbe8ae45/merck-drug-for-rare-tumour-hits-phase-3-target-pharmaphorum 2024-11-12T15:35:07+00:00 weekly 0.7 https://trial.medpath.com/news/0a06b3d3871151dc/how-pfizer-used-wearables-to-tap-into-the-promise-of-an-experimental-drug-stat-news 2024-11-12T15:31:41+00:00 weekly 0.7 https://trial.medpath.com/news/a72c7c6c18de3b79/first-line-triplet-therapy-for-advanced-stage-pik3ca-mutant-hr-breast-cancer-improves-outcomes 2024-11-12T15:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/e9c4d388db96b98e/buy-sell-or-hold-bmy-stock-forbes 2024-11-12T15:22:57+00:00 weekly 0.7 https://trial.medpath.com/news/3e68ed29f462a7d2/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T15:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/c97244a98011bfaa/springworks-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T15:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/860b38ce4c0a6c10/prominent-usc-scientist-goes-on-leave-amid-research-misconduct-allegations-national 2024-11-12T15:14:38+00:00 weekly 0.7 https://trial.medpath.com/news/9816c3674b180d7d/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T15:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/3374e227ae112060/zolbetuximab-plus-chemotherapy-offers-survival-benefits-in-treatment-naive-her2-onclive 2024-11-12T15:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/bfbbc0e5b84dab0d/arch-biopartners-doses-first-subject-in-trial-of-acute-kidney-injury-treatment 2024-11-12T15:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/4d33a31011a81093/multimodal-scanning-of-genetic-variants-with-base-and-prime-editing-nature-biotechnology 2024-11-12T15:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/703860a20fc12a24/seattle-children-s-now-enrolling-participants-for-first-u-s-car-t-cell-clinical-trial-for 2024-11-12T14:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/cb550900b1ce1283/ema-s-final-call-on-alzheimer-s-drug-leqembi-imminent-citeline 2024-11-12T14:53:33+00:00 weekly 0.7 https://trial.medpath.com/news/1578125bcdb0faa5/quantalx-secures-fda-clearance-for-its-breakthrough-delphi-stimulator-advancing-direct 2024-11-12T14:41:33+00:00 weekly 0.7 https://trial.medpath.com/news/50f30e50dbf93fc4/after-decades-of-work-an-atypical-schizophrenia-drug-is-approved 2024-11-12T14:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/816341b9d35efab2/refined-definition-of-platinum-resistance-novel-adcs-could-brind-more-changes-to-onclive 2024-11-12T14:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/a94169b84cfc85c6/komet-phase-iii-trial-met-primary-endpoint-shares-magazine 2024-11-12T14:22:23+00:00 weekly 0.7 https://trial.medpath.com/news/2ba1d29b0c99b253/summary-report-on-authorisation-givlaari-r-swissmedic 2024-11-12T14:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/16d872384f1378e3/fda-issues-crl-to-obeticholic-acid-ocaliva-denies-full-approval-for-pbc-hcplive 2024-11-12T14:19:05+00:00 weekly 0.7 https://trial.medpath.com/news/dde067f15733d0dd/cadrenal-therapeutics-highlights-presentation-at-european-yahoo-finance 2024-11-12T14:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/ae594bb1b161f49d/abbvie-s-disappointing-schizophrenia-drug-trial-bodes-well-for-rival-bristol-myers-analysts-say 2024-11-12T14:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/1cb72db15ef60db2/cadrenal-s-tecarfarin-shows-promise-for-lvad-patients-in-key-medical-congress-data 2024-11-12T14:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/689ffd43f8f15fbc/woolsey-pharmaceuticals-completes-patient-recruitment-for-high-dose-cohort-of-als-study 2024-11-12T14:05:46+00:00 weekly 0.7 https://trial.medpath.com/news/be6e2f37ec9f894f/cadrenal-therapeutics-highlights-presentation-at-european-placera 2024-11-12T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/9c6f213f4dd6a901/longboard-pharmaceuticals-initiates-phase-3-deep-ocean-study-evaluating-bexicaserin 2024-11-12T13:58:28+00:00 weekly 0.7 https://trial.medpath.com/news/c9506a95be26161e/aurobindo-unit-gets-ema-nod-for-biosimilar-facility-the-week 2024-11-12T13:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/4d9aa9188a2c5dc5/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-12T13:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/98c2aea0bacef0bb/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-12T13:28:17+00:00 weekly 0.7 https://trial.medpath.com/news/842834b1b3bee258/tonix-pharmaceuticals-reports-third-quarter-2024-financial-globenewswire 2024-11-12T13:27:03+00:00 weekly 0.7 https://trial.medpath.com/news/8b40fc6945b857c0/glyconex-announces-manufacturing-agreement-with-sterling-for-gnx102-adc-clinical-trial 2024-11-12T13:26:12+00:00 weekly 0.7 https://trial.medpath.com/news/26a04e6a5528504f/acuitive-technologies-receives-fda-510-k-clearance-for-globenewswire 2024-11-12T13:24:28+00:00 weekly 0.7 https://trial.medpath.com/news/ae579583e17969c2/icad-s-profound-detection-version-4-0-gains-fda-clearance-globenewswire 2024-11-12T13:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/02429850096daf28/savara-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-12T13:23:02+00:00 weekly 0.7 https://trial.medpath.com/news/d56415ad6120674c/j-j-submits-eu-and-us-applications-for-subcutaneous-darzalex-in-smouldering-multiple-myeloma 2024-11-12T13:17:11+00:00 weekly 0.7 https://trial.medpath.com/news/015d44e94087fece/enlivex-announces-the-enrollment-and-dosing-of-the-first-10-patient-in-the-randomized 2024-11-12T13:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/1f6cd697a7097e10/abbvie-s-stock-plummets-over-12-after-schizophrenia-drug-flops-in-phase-ii-trials 2024-11-12T13:17:02+00:00 weekly 0.7 https://trial.medpath.com/news/4e82d1c6cff1d742/moleculin-s-breakthrough-fda-fast-track-cancer-drug-advances-to-pivotal-phase-3-trial 2024-11-12T13:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/d7ab5f4a39750abd/enlivex-s-allocetra-advances-phase-ii-trial-launches-for-knee-osteoarthritis-treatment 2024-11-12T13:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/04d1bc2c62687ea3/moleculin-receives-institutional-review-board-approval-for-miracle-phase-3-pivotal-trial 2024-11-12T13:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/817df9260df84b74/tonix-pharmaceuticals-reports-third-quarter-2024-financial-results-and-operational-highlights 2024-11-12T13:06:56+00:00 weekly 0.7 https://trial.medpath.com/news/a7565ae44e19e7a7/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T13:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/94c78c29f2129aaa/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T12:52:09+00:00 weekly 0.7 https://trial.medpath.com/news/d4790d7b4ba3a9f3/genascence-granted-fda-fast-track-designation-for-gnsc-001-in-patients-with-pr-newswire 2024-11-12T12:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/5d5dfbf92f002b23/wave-life-sciences-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:44:07+00:00 weekly 0.7 https://trial.medpath.com/news/0bed933441aaa088/novavax-announces-fda-clinical-hold-lift-on-phase-3-covid-19-flu-vaccine-study-pmlive 2024-11-12T12:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/a74ecc4d18366de3/glyconex-announces-manufacturing-agreement-with-sterling-for-gnx102-adc-clinical-trial 2024-11-12T12:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/f8b9fc00cd2ed556/bridgebio-pharma-reports-third-quarter-2024-financial-results-and-business-update 2024-11-12T12:34:20+00:00 weekly 0.7 https://trial.medpath.com/news/33f468132f2c5656/spyre-s-ibd-drug-shows-breakthrough-90-day-half-life-in-phase-1-trial-4x-better-than-standard 2024-11-12T12:34:13+00:00 weekly 0.7 https://trial.medpath.com/news/177f1a178c7fadf3/abeona-therapeutics-r-announces-fda-acceptance-of-bla-globenewswire 2024-11-12T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/news/e416623f3f8ccd72/mereo-biopharma-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/8779a1412a519bbf/momentis-surgical-gets-fda-approval-for-second-generation-anovo-robotic-platform 2024-11-12T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/28548009b37a36d0/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T12:26:43+00:00 weekly 0.7 https://trial.medpath.com/news/225f17d85030b3d7/exostat-medical-receives-fda-clearance-for-novel-real-time-oral-tissue-perfusion 2024-11-12T12:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/e16ff004d3f5d966/multiomic-health-announces-discovery-of-novel-endotypes-and-biomarkers-for-diabetic 2024-11-12T12:23:55+00:00 weekly 0.7 https://trial.medpath.com/news/6df06ca6b07d1099/abbvie-s-stock-plummets-over-12-after-schizophrenia-drug-flops-in-phase-ii-trials 2024-11-12T12:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/e0d43fd2eb4d561f/chinese-regulator-raises-red-flag-on-clinical-trial-bribery-citeline 2024-11-12T12:17:23+00:00 weekly 0.7 https://trial.medpath.com/news/7280fff4dc2f86e9/iteos-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-12T12:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/ed8556bff93bc18e/zenas-biopharma-hits-milestone-completes-enrollment-in-largest-ever-igg4-rd-trial 2024-11-12T12:13:22+00:00 weekly 0.7 https://trial.medpath.com/news/8929c6b53564c4cb/nomic-r-and-parker-institute-for-cancer-immunotherapy-pici-launch-large-scale-news-medical 2024-11-12T12:12:48+00:00 weekly 0.7 https://trial.medpath.com/news/fe4d4d8872e20980/avadel-pharmaceuticals-provides-corporate-update-and-globenewswire 2024-11-12T12:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/135fff8feb7570ea/oncolytics-biotech-r-reports-third-quarter-2024-financial-results-and-operational-highlights 2024-11-12T12:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/2c4fff21daa18fec/autolus-therapeutics-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-12T12:07:44+00:00 weekly 0.7 https://trial.medpath.com/news/1c8f8191b815e204/bioxcel-therapeutics-advances-pivotal-phase-3-trials-of-globenewswire 2024-11-12T12:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/aefc69402cc6cb8f/axsome-therapeutics-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/29d484fca78e238c/autolus-therapeutics-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-12T12:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/98fa21bcab1b7500/formation-bio-collaborates-with-sanofi-and-openai-to-introduce-muse-a-first-of-its-kind-ai 2024-11-12T12:03:35+00:00 weekly 0.7 https://trial.medpath.com/news/4fe0a74eb36dc54a/belite-bio-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-12T12:02:42+00:00 weekly 0.7 https://trial.medpath.com/news/187ce2dd7fb4cb85/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-us-for-patients 2024-11-12T12:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/9fe0ee9b1f9645f4/zai-lab-announces-third-quarter-2024-financial-results-and-recent-corporate-updates 2024-11-12T11:58:42+00:00 weekly 0.7 https://trial.medpath.com/news/98bdf50fb4a2b612/astrazeneca-daiichi-sankyo-change-strategy-on-closely-watched-cancer-drug-stat-news 2024-11-12T11:58:04+00:00 weekly 0.7 https://trial.medpath.com/news/7788bbaacdfbb8af/show-chwan-health-care-system-joins-novotech-to-accelerate-the-quality-of-clinical-leader 2024-11-12T11:52:03+00:00 weekly 0.7 https://trial.medpath.com/news/d168a00f3b5caad9/koselugo-r-selumetinib-showed-significant-and-clinically-meaningful-improvement-in 2024-11-12T11:50:10+00:00 weekly 0.7 https://trial.medpath.com/news/bf51eb7d50e8e52a/ascletis-completes-phase-3-enrollment-for-novel-acne-drug-building-on-phase-2-success 2024-11-12T11:40:36+00:00 weekly 0.7 https://trial.medpath.com/news/691a8b68178e5c78/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T11:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/2cd98d4894fee006/viiv-healthcare-shares-results-from-trial-of-dovato-and-three-drug-therapy-for-hiv 2024-11-12T11:33:07+00:00 weekly 0.7 https://trial.medpath.com/news/ef4e79efd4be426b/arrowhead-pharmaceuticals-launches-awareness-campaign-for-fcs 2024-11-12T11:04:51+00:00 weekly 0.7 https://trial.medpath.com/news/099023dbb03f1dc8/rowan-based-startup-receives-fda-clearance-for-medical-technology 2024-11-12T11:02:49+00:00 weekly 0.7 https://trial.medpath.com/news/ca8ea65e6e9cf83d/scientific-leadership-spotlighted-as-gilead-presents-research-data-across-its-broad-and 2024-11-12T10:45:47+00:00 weekly 0.7 https://trial.medpath.com/news/d70048a5bdc727d3/lipella-pharmaceuticals-secures-extended-market-exclusivity-globenewswire 2024-11-12T10:32:25+00:00 weekly 0.7 https://trial.medpath.com/news/0119f5b2b197fa82/syncona-proud-but-not-revived-by-autolus-winning-fda-approval-citywire 2024-11-12T10:26:11+00:00 weekly 0.7 https://trial.medpath.com/news/2adf3bcd55ac2b87/autolus-car-t-aucatzyl-wins-us-fda-nod-for-leukemia-bioworld 2024-11-12T10:09:10+00:00 weekly 0.7 https://trial.medpath.com/news/a6313fea4eb792e0/revolutionising-heart-health-frontier-x-plus-gains-fda-approval-aw-athletics-weekly 2024-11-12T10:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/81b998a5ab7d8779/merck-kgaa-phase-iii-trial-of-pimicotinib-in-tenosynovial-giant-cell-tumor-meets-primary-endpoint 2024-11-12T09:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/756654bdd0328919/fda-grants-breakthrough-status-to-j-j-s-nipocalimab-for-sjd-treatment 2024-11-12T09:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/0a4d1cabb3756ee3/astra-invests-3-5-billion-in-us-as-cancer-drug-lifts-sales-bnn-bloomberg 2024-11-12T09:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/12e78fe97daa697b/merck-kgaa-phase-iii-trial-of-pimicotinib-in-tenosynovial-giant-cell-tumor-meets-primary-endpoint 2024-11-12T09:07:59+00:00 weekly 0.7 https://trial.medpath.com/news/9a8d2a3ef76f7c6c/nipocalimab-gets-fda-breakthrough-status-tradingview 2024-11-12T08:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/16239f802c69dfd3/tdf-litigation-gilead-sciences 2024-11-12T08:40:24+00:00 weekly 0.7 https://trial.medpath.com/news/101143fd3887ea03/astrazeneca-koselugo-phase-iii-trial-meets-primary-goal-in-adults-with-neurofibromatosis-type-1 2024-11-12T08:29:46+00:00 weekly 0.7 https://trial.medpath.com/news/23168c0eba2bcf04/nanobiotix-provides-third-quarter-2024-update-and-progress-on-nanotherapeutics-platforms 2024-11-12T07:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/7d29f3048ef68140/koselugo-showed-statistically-significant-and-clinically-meaningful-objective-response-rate 2024-11-12T07:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/65c45a11b6b1f91e/johnson-johnson-announces-u-s-food-and-drug-administration-grants-nipocalimab 2024-11-12T07:01:02+00:00 weekly 0.7 https://trial.medpath.com/news/42cd7c615358a3bd/belite-bio-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-12T06:38:10+00:00 weekly 0.7 https://trial.medpath.com/news/f3a892b2418ebccd/relacorilant-plus-nab-paclitaxel-carves-new-avenues-of-platinum-resistant-ovarian-cancer-care 2024-11-12T06:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/47a259f14f9ffd4c/pimicotinib-significantly-improved-outcomes-for-patients-with-tenosynovial-giant-cell 2024-11-12T06:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/b88fdd72b1cac53e/long-term-analysis-shows-tafinlar-plus-mekinist-reduces-mortality-risk-in-stage-iii-melanoma 2024-11-12T06:17:59+00:00 weekly 0.7 https://trial.medpath.com/news/6060fdc8a08582fc/optimizing-clinical-trial-efficiency-the-power-of-simplicity-for-first-in-human-studies 2024-11-12T06:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/8781bd29cd28f701/kancera-focuses-on-cardiovascular-diseases-placera 2024-11-12T06:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/fc0878c4d42f61f9/early-treatment-of-hepatitis-b-is-key-to-preventing-liver-cancer-and-reducing-healthcare-costs 2024-11-12T05:50:45+00:00 weekly 0.7 https://trial.medpath.com/news/1b5fb0483b65be51/phase-i-clinical-trial-of-pembrolizumab-and-denileukin-diftitox-in-patients-with-recurrent 2024-11-12T05:35:34+00:00 weekly 0.7 https://trial.medpath.com/news/c8a791c4ae8b693d/organogenesis-phase-3-trial-success-renu-knee-treatment-shows-promising-results 2024-11-12T05:05:25+00:00 weekly 0.7 https://trial.medpath.com/news/53bfb6b0889b445b/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-marketscreener 2024-11-12T03:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/7dc5dda933d6891e/recordati-s-isturisa-wins-korean-approval-to-treat-cusing-s-disease-pharma-article-kbr 2024-11-12T02:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/8e7f94d17176c30d/what-s-behind-the-insider-buying-on-this-high-yield-stock-the-globe-and-mail 2024-11-12T01:49:43+00:00 weekly 0.7 https://trial.medpath.com/news/16a3783c716842eb/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-12T00:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/77721d244638a13b/chinese-regulator-raises-red-flag-on-clinical-trial-bribery 2024-11-12T00:17:24+00:00 weekly 0.7 https://trial.medpath.com/news/bebe4417d5c225a0/johnson-johnson-gets-breakthrough-therapy-designation-for-sjogren-s-disease-treatment 2024-11-12T00:07:43+00:00 weekly 0.7 https://trial.medpath.com/news/6aab1cd402c8ac6a/allo-316-shows-50-response-rate-in-cd70-positive-rcc-in-phase-1-trial 2024-11-12T00:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/39b7699d045a7a69/johnson-johnson-gets-breakthrough-therapy-designation-for-sjogren-s-disease-treatment 2024-11-12T00:00:16+00:00 weekly 0.7 https://trial.medpath.com/news/d4008facf707bb69/cogent-biosciences-reports-recent-business-highlights-and-third-quarter-2024-financial-results 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/498ce9c8254b0691/singapore-launches-asia-s-first-mrna-biofoundry-to-advance-nucleic-acid-therapeutics 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a3a27406a294b8e0/citius-pharmaceuticals-lymphir-and-keytruda-combo-shows-promising-clinical-outcomes-earning-a-buy-rating 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8c3a6e55bf450697/fda-lifts-clinical-hold-on-novavax-s-trials-for-covid-19-influenza-combination 2024-11-11T23:27:07+00:00 weekly 0.7 https://trial.medpath.com/news/aedfc1b50ed9ebf9/bostongene-sweeps-2024-pharmaceutical-excellence-awards-with-ai-powered-cancer-diagnostics-platform 2024-11-11T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c10822a4e17e518c/value-of-abbvie-s-cerevel-buy-uncertain-after-schizophrenia-failure-citeline 2024-11-11T22:52:05+00:00 weekly 0.7 https://trial.medpath.com/news/91ca3f5dfa300520/nk-cell-therapy-clinical-trial-pipeline-appears-robust-with-140-key-pharma-pr-newswire 2024-11-11T22:34:55+00:00 weekly 0.7 https://trial.medpath.com/news/23960a3ed74e9316/on-wall-street-flat-out-failure-of-abbvie-schizophrenia-drug-leaves-analysts-stunned 2024-11-11T22:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/618eac39b5a6da5a/zongertinib-a-promising-new-tki-for-her2-mutated-nsclc-pharmacy-times 2024-11-11T22:27:32+00:00 weekly 0.7 https://trial.medpath.com/news/49d5d08011c846cd/abbvie-tumbles-after-new-schizophrenia-drug-fails-two-trials-yahoo-finance 2024-11-11T22:19:25+00:00 weekly 0.7 https://trial.medpath.com/news/84fc5d0f8c2007a0/eureka-therapeutics-tackling-advanced-hepatocellular-carcinoma-with-t-cell-therapy 2024-11-11T22:14:12+00:00 weekly 0.7 https://trial.medpath.com/news/3357242e2c9b0a6e/aberdeen-woman-says-blood-cancer-drug-approval-could-give-her-chance-of-more-normal-life 2024-11-11T22:05:14+00:00 weekly 0.7 https://trial.medpath.com/news/49a3d570be8443e9/impact-of-cable-lock-distribution-on-firearm-securement-after-emergent-mental-health-evaluation 2024-11-11T21:48:33+00:00 weekly 0.7 https://trial.medpath.com/news/840e254c49a8a35d/fda-grants-nipocalimab-second-breakthrough-therapy-designation-investing-com 2024-11-11T21:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/dde8e2292e369025/spyre-therapeutics-to-host-conference-call-and-webcast-to-report-interim-results-morningstar 2024-11-11T21:45:55+00:00 weekly 0.7 https://trial.medpath.com/news/44b034bd3177871e/adding-targeted-agent-to-perioperative-therapy-for-rcc-may-improve-disease-control 2024-11-11T21:38:42+00:00 weekly 0.7 https://trial.medpath.com/news/807f27d9b156b61e/sonoma-pharma-secures-fda-clearance-for-enhanced-wound-care-hydrogel-technology 2024-11-11T21:37:26+00:00 weekly 0.7 https://trial.medpath.com/news/a109dc79f8251934/mineralys-therapeutics-reports-third-quarter-2024-financial-results-and-provides 2024-11-11T21:21:27+00:00 weekly 0.7 https://trial.medpath.com/news/763ec98a78d68088/quince-therapeutics-presents-safety-data-from-prior-phase-3-attest-clinical-trial-at-53rd 2024-11-11T21:21:25+00:00 weekly 0.7 https://trial.medpath.com/news/3545bf15cb55aeb6/quince-therapeutics-erydex-shows-promising-safety-data-in-phase-3-a-t-trial-qncx-stock-news 2024-11-11T21:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/dc62893c9e582860/livanova-announces-osprey-clinical-study-meets-primary-safety-and-efficacy-endpoints 2024-11-11T21:20:51+00:00 weekly 0.7 https://trial.medpath.com/news/a90795da7741574a/nipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough 2024-11-11T21:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/cb9f25ab836a002f/thio-combo-shows-enduring-activity-in-advanced-non-small-cell-lung-cancer 2024-11-11T21:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/e0c1979c42d2809a/fda-approves-new-immunotherapy-for-aggressive-leukemia-webmd 2024-11-11T21:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/c25217ae3527000d/major-immunotherapy-trial-sees-survival-benefit-in-solid-tumours 2024-11-11T20:51:28+00:00 weekly 0.7 https://trial.medpath.com/news/e6d182807b2d906d/is-rapamycin-the-next-big-breakthrough-in-periodontitis-and-oral-cancer-treatment 2024-11-11T20:49:56+00:00 weekly 0.7 https://trial.medpath.com/news/a43098ed0159b053/perioperative-tislelizumab-with-four-cycles-of-neoadjuvant-chemotherapy-for-resectable 2024-11-11T20:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/a69cd4949d134dde/sngx-phase-3-ctcl-trial-to-initiate-before-end-of-2024-zacks-small-cap-research 2024-11-11T20:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/04a3f5021112d275/johnson-johnson-seeks-fda-approval-of-daratumumab-for-smoldering-multiple-myeloma 2024-11-11T20:28:24+00:00 weekly 0.7 https://trial.medpath.com/news/2fbd01df6547d59f/aaopt-2024-running-the-numbers-on-ophthalmic-clinical-trials-optometry-times 2024-11-11T20:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/0f406105e0d3f1e3/bristol-myers-squibb-s-stock-soars-after-rival-abbvie-reports-disappointing-schizophrenia-drug-trial 2024-11-11T20:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/418046370b8c2d0d/dosing-of-first-patient-in-a-trial-for-lsalt-peptide-is-sending-shares-higher 2024-11-11T20:07:36+00:00 weekly 0.7 https://trial.medpath.com/news/9eaa31feff0964eb/unicycive-eyes-june-fda-verdict-for-hyperphosphataemia-drug-pharmaphorum 2024-11-11T19:48:41+00:00 weekly 0.7 https://trial.medpath.com/news/d64b8b728ca5789b/scientists-use-microcellular-drones-to-deliver-lung-cancer-killing-drugs 2024-11-11T19:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/9b43505edfbcc6f7/largest-t-cell-clinical-trial-in-solid-tumors-explores-potential-for-precision-immunotherapy 2024-11-11T19:19:53+00:00 weekly 0.7 https://trial.medpath.com/news/b2cd650a69654962/neurogene-reports-positive-interim-efficacy-data-from-first-four-low-dose-pediatric-participants-in-ngn-401-gene-therapy-clinical-trial-for-rett-syndrome 2024-11-11T19:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/7282443b96620c32/abbvie-s-emraclidine-fails-to-reduce-schizophrenia-symptoms-compared-to-placebo 2024-11-11T18:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/4f9d25df0984a59c/arch-biopartners-announces-dosing-of-first-patient-in-canada-in-the-phase-ii-trial-for-stockhouse 2024-11-11T18:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/abec32b173181f5b/efficacy-of-combined-administration-of-baekhogainsam-tang-and-low-dose-pilocarpine-on 2024-11-11T18:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/e1553bbd22e5456a/abbvie-drug-expected-to-rival-bristol-myers-s-new-schizophrenia-med-flunks-phase-2-test 2024-11-11T18:26:58+00:00 weekly 0.7 https://trial.medpath.com/news/7cf42e8cc33344e0/multifunctional-antibody-shows-promise-for-treating-several-types-of-cancer-medical-xpress 2024-11-11T18:24:59+00:00 weekly 0.7 https://trial.medpath.com/news/b9cf79680d875404/early-serum-il-2-levels-are-associated-with-car-t-cell-expansion-post-car-t-cell-therapy 2024-11-11T18:23:53+00:00 weekly 0.7 https://trial.medpath.com/news/8e1d1eac67b28812/a-selective-bcl-2-inhibitor-with-improved-efficacy-against-known-treatment-resistant-mutants 2024-11-11T18:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/9b074c7cfec1558e/novavax-gets-fda-approval-to-resume-testing-two-vaccines-after-clinical-hold 2024-11-11T18:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/31cb3edd1302f991/french-biotech-company-adipopharma-secures-funding-to-initiate-clinical-trials-for-its-first 2024-11-11T17:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/c8c094363044c906/french-biotech-company-adipopharma-secures-funding-to-initiate-clinical-trials-for-its-first 2024-11-11T17:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/2c6809814f73cb35/french-biotech-company-adipopharma-secures-funding-to-globenewswire 2024-11-11T17:46:58+00:00 weekly 0.7 https://trial.medpath.com/news/0f3a16d8a293c0b7/herbal-placebo-response-in-clinical-trials-on-irritable-bowel-syndrome-a-systematic-review 2024-11-11T17:43:44+00:00 weekly 0.7 https://trial.medpath.com/news/048dcb48f7183788/abbvie-stock-sinks-after-schizophrenia-drug-trials-disappoint-investopedia 2024-11-11T17:38:49+00:00 weekly 0.7 https://trial.medpath.com/news/12bd25534b20e21d/fda-approves-new-car-t-competitor-to-gilead-s-tecartus-biopharma-dive 2024-11-11T17:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/380ad09fb60c26fe/fda-lifts-pause-on-novavax-flu-vaccine-trials-biopharma-dive 2024-11-11T17:16:27+00:00 weekly 0.7 https://trial.medpath.com/news/5c5620b06cd713f6/theragent-and-cellvax-therapeutics-announce-first-patient-dosed-in-phase-2-trial-of-fk 2024-11-11T17:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/4082edde992f252c/fda-delays-priority-review-of-neurotech-s-eye-cell-therapy-implant 2024-11-11T17:11:50+00:00 weekly 0.7 https://trial.medpath.com/news/f03f24d9154a034e/based-on-recent-fda-feedback-rapt-therapeutics-stops-zelnecirnon-program-following 2024-11-11T17:11:39+00:00 weekly 0.7 https://trial.medpath.com/news/accb0ea09f61eb39/lumateperone-demonstrates-positive-efficacy-for-schizophrenia-relapse-prevention 2024-11-11T17:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/642dbe1960387e64/an-overlook-of-cagrilintinide-and-semaglutide-as-it-progresses-through-phase-3-trials 2024-11-11T17:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/3cc9ec34960373db/fda-approves-obecabtagene-autoleucel-for-adults-with-relapsed-or-refractory-b-cell 2024-11-11T17:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/ded4ad62f6ee22e7/abbvie-s-9b-bet-collapses-as-closely-watched-schizophrenia-drug-fails-studies 2024-11-11T16:56:58+00:00 weekly 0.7 https://trial.medpath.com/news/5cb6d5a1053eb3bc/autolus-secures-fda-approval-for-car-t-cell-therapy-use-in-all 2024-11-11T16:56:43+00:00 weekly 0.7 https://trial.medpath.com/news/a2a7169ff4891d19/tempus-study-combined-rna-dna-testing-boosts-lung-cancer-detection-by-15-3 2024-11-11T16:48:19+00:00 weekly 0.7 https://trial.medpath.com/news/411b382c919684b4/citius-phase-1-trial-shows-27-response-rate-with-lymphir-keytruda-combo-in-cancer-study 2024-11-11T16:48:19+00:00 weekly 0.7 https://trial.medpath.com/news/92717367118cf988/moleculin-biotech-advances-phase-3-trial-as-q3-shows-mixed-financial-results-mbrx-stock-news 2024-11-11T16:46:37+00:00 weekly 0.7 https://trial.medpath.com/news/d4bb419e20f3be78/abbvie-provides-update-on-phase-2-results-for-emraclidine-in-schizophrenia 2024-11-11T16:46:26+00:00 weekly 0.7 https://trial.medpath.com/news/8c6c899e93bba74a/rapt-therapeutics-shares-tumble-by-48-after-zelnecirnon-programme-cull 2024-11-11T16:40:02+00:00 weekly 0.7 https://trial.medpath.com/news/884667caf9a86d1d/gilead-and-merck-report-successful-phase-2-results-for-investigational-once-weekly-hiv-treatment 2024-11-11T16:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/50a8603174d4777e/ideaya-s-ide034-breakthrough-first-in-class-cancer-drug-shows-dual-target-promise 2024-11-11T16:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/92139e87e4480260/impact-of-vancomycin-therapeutic-drug-monitoring-on-mortality-in-sepsis-patients-across 2024-11-11T16:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/b2f2e5c47b6d02af/abbvie-shares-plummet-12-as-cerevel-schizophrenia-asset-fails-phase-ii-trials 2024-11-11T16:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/49661a0306b73845/disc-medicine-secures-200m-financing-to-support-trials 2024-11-11T16:15:52+00:00 weekly 0.7 https://trial.medpath.com/news/54bd8852ad6036a5/bristol-myers-squibb-s-stock-soars-after-rival-abbvie-reports-disappointing-schizophrenia-drug-trial 2024-11-11T16:11:57+00:00 weekly 0.7 https://trial.medpath.com/news/a02c37903b36f539/abbvie-stock-tumbles-on-failed-schizophrenia-drug-studies-bristol-myers-jumps 2024-11-11T16:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/52e21176a0d529b2/advantage-bms-as-abbvie-drug-fails-schizophrenia-trials-pharmaphorum 2024-11-11T16:06:54+00:00 weekly 0.7 https://trial.medpath.com/news/a9f9cdf04893fed3/real-world-survival-outcomes-in-mcspc-comparison-of-apalutamide-and-abiraterone 2024-11-11T16:06:11+00:00 weekly 0.7 https://trial.medpath.com/news/6eec68971d982fbd/intratracheal-budesonide-mixed-with-surfactant-for-extremely-preterm-infants-jama-network 2024-11-11T16:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/44cb6360f3df730b/abbvie-sheds-38bn-in-value-after-failing-schizophrenia-drug-trials-nyse-abbv 2024-11-11T16:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/f04edf089b8d562a/aaopt-2024-preserving-vision-by-detecting-and-treating-ga 2024-11-11T15:55:01+00:00 weekly 0.7 https://trial.medpath.com/news/4e79c1f6159c69a3/astrazeneca-tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in 2024-11-11T15:53:04+00:00 weekly 0.7 https://trial.medpath.com/news/bcd352ffc5abf479/ainos-announces-irb-approval-for-sjogren-s-syndrome-clinical-study-tipranks-com 2024-11-11T15:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/2ec2228480de85a0/chimerix-announces-updated-phase-2-response-assessment-of-dordaviprone-in-ein-presswire 2024-11-11T15:43:57+00:00 weekly 0.7 https://trial.medpath.com/news/db65cbf59d5cc3e5/fda-grants-clearance-for-phase-1-trial-of-bl-m17d1-in-solid-tumors-targeted-oncology 2024-11-11T15:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/641429845172c484/dana-farber-researchers-hijack-gut-bacteria-to-design-novel-form-of-cancer-immunotherapy 2024-11-11T15:39:19+00:00 weekly 0.7 https://trial.medpath.com/news/f32c5f694a76b4d1/sandoz-launches-generic-paclitaxel-in-single-dose-vial-drug-store-news 2024-11-11T15:38:37+00:00 weekly 0.7 https://trial.medpath.com/news/20c6ff28c721c9d6/improving-precision-of-vaccine-efficacy-evaluation-using-immune-correlate-data-in-time-to 2024-11-11T15:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/71f39ac9f2f0039e/theragent-and-cellvax-therapeutics-announce-first-patient-dosed-in-phase-2-trial-of-fk 2024-11-11T15:21:41+00:00 weekly 0.7 https://trial.medpath.com/news/95933314f1115eba/citius-lymphir-shows-potential-to-boost-pembrolizumab-efficacy-contract-pharma 2024-11-11T15:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/eea745a5be029344/parkinson-s-disease-clinical-research-in-seven-major-markets-focuses-on-disease-modifying-agents 2024-11-11T15:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/1c5955f7aaf226bc/spravato-is-just-the-beginning-in-a-new-wave-of-depression-meds-pharmavoice 2024-11-11T15:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/15b34ff3766a97cd/trial-shows-acupuncture-is-feasible-for-reducing-pain-in-the-emergency-department 2024-11-11T15:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/a1d7cf02bcaa5ecb/abbvie-tumbles-after-new-schizophrenia-drug-fails-two-trials-yahoo-finance 2024-11-11T15:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/6d5a43daddd2c164/glp-1-and-sglt2-drugs-may-help-prevent-second-strokes-and-heart-attacks-in-stroke-survivors 2024-11-11T15:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/5ad72d2f97ea8c41/innovative-approaches-to-gynecologic-cancer-prognosis-fueled-by-metabolomics 2024-11-11T15:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/d3dead63eba15aeb/uk-mhra-at-least-half-of-novel-drug-filings-to-take-national-assessment-route 2024-11-11T14:46:09+00:00 weekly 0.7 https://trial.medpath.com/news/b416ee010a2d0e62/citius-lymphir-shows-potential-to-boost-pembrolizumab-efficacy-contract-pharma 2024-11-11T14:39:59+00:00 weekly 0.7 https://trial.medpath.com/news/c4a499e3661e189e/emraclidine-for-schizophrenia-fails-to-meet-primary-endpoints-in-phase-2-empower-trials 2024-11-11T14:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/0970f28178ca4935/rapt-crashes-after-axing-atopic-dermatitis-asthma-hopeful-cites-liver-injury-biospace 2024-11-11T14:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/b1b2fc67cdf0f499/ema-benefits-from-astrazeneca-significantly-outweigh-side-effects-telegraph-telegraph 2024-11-11T14:34:36+00:00 weekly 0.7 https://trial.medpath.com/news/aa94f741a1c7c649/viiv-healthcare-announces-data-demonstrating-dovato-dtg-3tc-is-highly-effective-in 2024-11-11T14:31:35+00:00 weekly 0.7 https://trial.medpath.com/news/c00aefbc0938d8db/bristol-myers-rockets-12-after-abbvie-s-schizophrenia-drug-fails 2024-11-11T14:27:52+00:00 weekly 0.7 https://trial.medpath.com/news/9f1a3dbd9f1e9a27/schizophrenia-drug-abbvie-picked-up-in-9-billion-acquisition-fails-in-key-trials-stat-news 2024-11-11T14:26:47+00:00 weekly 0.7 https://trial.medpath.com/news/76c03a78216e91ea/abbvie-shares-slip-after-schizophrenia-drug-trial-misses-primary-endpoint-yahoo-finance 2024-11-11T14:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/676f272dc730ddaa/review-of-fda-approved-jak-inhibitors-for-alopecia-areata-hcplive 2024-11-11T14:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/8e585e2922f72257/how-pharmacists-can-make-an-impact-when-treating-dedifferentiated-liposarcoma-with 2024-11-11T14:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/62ae44e829bb2087/iterum-s-sulopenem-receives-fda-approval-for-treatment-of-uncomplicated-urinary-tract-infections 2024-11-11T14:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/de0d6cc41296c498/fda-receives-application-seeking-approval-of-darzalex-faspro-in-smoldering-myeloma 2024-11-11T14:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/8cc39fe5607cd27a/resq-pharma-receives-pdufa-date-for-lipidrescuetm-as-a-potential-first-ever-fda 2024-11-11T13:57:02+00:00 weekly 0.7 https://trial.medpath.com/news/953fd38d29aa44ab/citius-pharmaceuticals-inc-and-citius-oncology-inc-announce-promising-pr-newswire 2024-11-11T13:50:47+00:00 weekly 0.7 https://trial.medpath.com/news/b23978b6d650efc9/inflammatix-initiates-triveritytm-for-improved-management-of-emergency-department 2024-11-11T13:48:52+00:00 weekly 0.7 https://trial.medpath.com/news/306ec828164990a3/tempus-publishes-study-highlighting-benefits-of-concurrent-rna-and-dna-sequencing-in 2024-11-11T13:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/2bcc07e94ba608b8/your-health-blood-test-breakthrough-revolutionizing-postpartum-depression-wafb 2024-11-11T13:41:12+00:00 weekly 0.7 https://trial.medpath.com/news/5ed31f911ae3f651/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-11T13:38:42+00:00 weekly 0.7 https://trial.medpath.com/news/91a8caaac9a1194b/tivozanib-monotherapy-outperforms-combination-therapy-in-post-ici-rcc-nature 2024-11-11T13:35:30+00:00 weekly 0.7 https://trial.medpath.com/news/8aaf4c4dc5b48131/intellia-therapeutics-q3-earnings-report-puts-phase-ii-results-in-focus-nasdaq-ntla 2024-11-11T13:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/f88b5a761364e50f/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-11T13:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/8750abcb551c3908/unicycive-says-fda-accepts-nda-for-oxylanthanum-carbonate-to-treat-patients-with-ckd 2024-11-11T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/news/f95294dbeccac1b9/kills-ovarian-cancer-without-toxicity-in-key-study-cero-stock-news 2024-11-11T13:22:59+00:00 weekly 0.7 https://trial.medpath.com/news/a4e7061bd4b3031b/rapt-therapeutics-halts-key-drug-program-after-fda-safety-concerns-liver-injury 2024-11-11T13:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/bfcc37d961cd4513/first-in-class-bispecific-antibody-alg-apv-527-meets-important-trial-endpoints-in-phase-1 2024-11-11T13:18:58+00:00 weekly 0.7 https://trial.medpath.com/news/9c6b659318c42f32/cg-oncology-announces-nature-medicine-publication-of-phase-globenewswire 2024-11-11T13:15:59+00:00 weekly 0.7 https://trial.medpath.com/news/af40afbfc91cc00b/annovis-bio-reports-third-quarter-financial-results-and-provides-business-update 2024-11-11T13:15:54+00:00 weekly 0.7 https://trial.medpath.com/news/7c0acc991f699a70/astrazeneca-amgen-s-tezspire-shows-promise-in-phase-3-crswnp-trial-pmlive 2024-11-11T13:15:53+00:00 weekly 0.7 https://trial.medpath.com/news/3d2c2f14d743c9cd/fda-approves-autolus-aucatzyl-to-treat-acute-lymphoblastic-leukaemia-pmlive 2024-11-11T13:15:49+00:00 weekly 0.7 https://trial.medpath.com/news/7a93a15d0b653e32/scottish-medicines-consortium-approves-car-t-cell-therapy-for-blood-cancer 2024-11-11T13:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/803d25c4cee7baa5/improving-alzheimer-diagnosis-with-innovative-blood-based-biomarker-tests-and-bd-tau 2024-11-11T13:13:16+00:00 weekly 0.7 https://trial.medpath.com/news/9e509a7a13039ca3/nammi-therapeutics-doses-first-subject-in-trial-of-qxl138am-for-multiple-myeloma 2024-11-11T13:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/bfc00c95b38bfe57/ainos-announces-irb-approval-for-sjogren-s-syndrome-clinical-study-at-shuang-ho 2024-11-11T13:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/a406ccee9fe59494/aethlon-medical-reaches-key-milestone-with-enrollment-of-the-first-patient-in-fpi-markets-data 2024-11-11T13:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/00dc4551a2f93967/phase-1-study-of-isatuximab-monotherapy-in-chinese-patients-with-relapsed-refractory 2024-11-11T13:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/32d92e6433686ef4/ainos-advances-sjogren-s-treatment-key-trial-for-veldona-r-gets-irb-green-light 2024-11-11T13:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/4528e131744b9a8e/annovis-bio-gets-fda-nod-for-phase-3-alzheimer-s-trial-cuts-losses-40-in-q3-anvs-stock-news 2024-11-11T13:05:22+00:00 weekly 0.7 https://trial.medpath.com/news/6fd52dc837c80a7b/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T13:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/f5d948ffd283d388/chimerix-announces-updated-phase-2-response-assessment-of-dordaviprone-in-morningstar 2024-11-11T13:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/67dd04cdd1f77bfa/boston-scientific-resumes-enrolment-in-pulsed-field-ablation-trial-clinical-trials-arena 2024-11-11T13:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/4ca87effd47aae41/groundbreaking-research-finds-that-alzheimer-s-can-be-transmitted-between-people 2024-11-11T12:49:43+00:00 weekly 0.7 https://trial.medpath.com/news/7cc018351a8cfb46/alembic-receives-usfda-final-approval-for-diltiazem-hydrochloride-er-capsules 2024-11-11T12:48:34+00:00 weekly 0.7 https://trial.medpath.com/news/8e5f76cfac7783ba/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-4015089-yahoo-finance 2024-11-11T12:39:55+00:00 weekly 0.7 https://trial.medpath.com/news/f1bd6f32b3727952/moleculin-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-11T12:39:14+00:00 weekly 0.7 https://trial.medpath.com/news/11727572a03cfa08/arch-biopartners-announces-dosing-of-first-patient-in-canada-in-the-phase-ii-trial-for 2024-11-11T12:35:17+00:00 weekly 0.7 https://trial.medpath.com/news/8d2752fa4c1890be/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-4015089-stock-titan 2024-11-11T12:34:55+00:00 weekly 0.7 https://trial.medpath.com/news/b3375e89e4785e2c/arch-biopartners-announces-dosing-of-first-patient-in-globenewswire 2024-11-11T12:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/4656495cb90b283f/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T12:26:41+00:00 weekly 0.7 https://trial.medpath.com/news/087e8275c1521d5a/gastric-cancer-awareness-month-2024-looking-back-at-progress-for-cell-therapy-cgtlive-r 2024-11-11T12:20:08+00:00 weekly 0.7 https://trial.medpath.com/news/5011c9fb9ee9a8b5/ethics-approval-received-in-indonesia-to-commence-dosing-in-a-registrational-phase-3 2024-11-11T12:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/75840516f5e34346/astrazeneca-amgen-claim-late-stage-win-in-chronic-rhinosinusitis-but-analyst-flags 2024-11-11T12:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/8a1c6fec902def01/can-fite-launches-phase-iia-trial-for-fda-designated-orphan-drug-in-pancreatic-cancer 2024-11-11T12:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/670e5a31b740f59f/chimerix-cancer-drug-shows-28-response-rate-in-phase-2-brain-tumor-trial-cmrx-stock-news 2024-11-11T12:06:47+00:00 weekly 0.7 https://trial.medpath.com/news/b4d5e1d4f147688b/springworks-therapeutics-announces-mirdametinib-data-to-be-presented-at-the-2024-stock-titan 2024-11-11T12:06:47+00:00 weekly 0.7 https://trial.medpath.com/news/888595b973bc61bb/moleculin-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-11T12:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/69dadb8604fea73d/momentis-surgical-receives-fda-510-k-clearance-for-second-generation-anovo-r-robotic 2024-11-11T12:05:52+00:00 weekly 0.7 https://trial.medpath.com/news/39ddf3403af76e2c/unicycive-therapeutics-announces-u-s-fda-acceptance-of-the-globenewswire 2024-11-11T12:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/4cd22ee2e2b5fb67/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T12:04:28+00:00 weekly 0.7 https://trial.medpath.com/news/24675fcd74775b80/unicycive-s-kidney-disease-drug-gets-fda-review-date-aims-for-2025-launch-uncy-stock-news 2024-11-11T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/8ad06ec0c7bb0f68/australian-german-research-finds-world-first-cure-for-deadly-skin-disease-daijiworld-com 2024-11-11T11:38:36+00:00 weekly 0.7 https://trial.medpath.com/news/716cf953242fa9a7/paratek-s-antibiotic-succeeds-in-phase-iib-lung-disease-trial 2024-11-11T11:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/1e548e70ceaf6407/springworks-therapeutics-announces-publication-of-the-pivotal-phase-2b-reneu-trial 2024-11-11T11:33:23+00:00 weekly 0.7 https://trial.medpath.com/news/540239cbe4109b70/ideaya-announces-development-candidate-nomination-of-ide034-a-potential-first-in 2024-11-11T11:31:44+00:00 weekly 0.7 https://trial.medpath.com/news/b01ed31166fb5cc7/alembic-pharmaceuticals-gains-us-fda-approval-for-diltiazem-capsules-to-treat-hypertension 2024-11-11T11:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/dc00a926e592394d/biocytogen-announces-ideaya-s-nomination-of-development-candidate-ide034-a-via-ritzau 2024-11-11T11:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/b248579277957250/ema-grants-limited-market-designation-to-vivesto-s-paccal-vet-marketscreener 2024-11-11T11:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/79c3599566f38908/moderna-bags-health-canada-nod-for-rsv-vaccine-for-adults-aged-60-years-and-older 2024-11-11T11:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/eb58463b89938945/patient-with-sickle-cell-disease-dies-from-complications-related-to-busulfan-conditioning 2024-11-11T11:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/2da7d928593f4bf7/weight-loss-meds-help-stroke-survivors-prevent-stroke-recurrence-death 2024-11-11T11:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/5b00146ee0f2ac75/hourglass-shaped-stent-might-ease-tough-to-treat-angina 2024-11-11T11:04:32+00:00 weekly 0.7 https://trial.medpath.com/news/32a3da7bd0acdbc1/trbc1-car-t-cell-therapy-in-peripheral-t-cell-lymphoma-a-phase-1-2-trial-nature 2024-11-11T10:58:32+00:00 weekly 0.7 https://trial.medpath.com/news/c7fad5162b8cf77c/vivesto-s-paccal-vet-receives-limited-market-classification-in-eu-tradingview-news 2024-11-11T10:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/7e9215f8a0dad02d/alembic-pharma-receives-usfda-approval-for-hypertension-drug-equitypandit 2024-11-11T10:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/ff4826efd777bbc0/moderna-s-mresvia-vaccine-gains-health-canada-approval-pharmaceutical-technology 2024-11-11T10:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/eb0fbc77cad87e9f/syncona-s-autolus-wins-fda-approval-for-aggressive-leukaemia-therapy-marketscreener 2024-11-11T10:38:28+00:00 weekly 0.7 https://trial.medpath.com/news/debd42ee23abb6dd/syncona-s-autolus-wins-fda-approval-for-aggressive-leukaemia-therapy-morningstar 2024-11-11T10:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/d929823b590df195/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-11T10:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/7edea26b38fb496f/data-fomo-may-undermine-clinical-trials-roi-phesi-warns-laboratory-news 2024-11-11T10:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/e129cc8f26a8ed07/tectonic-therapeutic-announces-positive-phase-1a-results-in-globenewswire 2024-11-11T10:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/60f64ef64ed6d32f/palleon-pharmaceuticals-reports-phase-i-ii-trial-results-of-e-602-for-solid-tumours 2024-11-11T09:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/3781524a5f19b589/alembic-pharmaceuticals-gets-usfda-nod-for-generic-hypertension-treatment-capsules 2024-11-11T09:42:36+00:00 weekly 0.7 https://trial.medpath.com/news/fa615d94ac8cc9b7/autolus-bags-fda-approval-for-leukaemia-cell-therapy-pharmaphorum 2024-11-11T09:35:20+00:00 weekly 0.7 https://trial.medpath.com/news/d5cd8dfcb8a3453e/alembic-pharmaceuticals-gains-usfda-final-approval-for-diltiazem-hydrochloride-extended 2024-11-11T09:33:59+00:00 weekly 0.7 https://trial.medpath.com/news/e80ff51b279097dd/will-adlai-be-the-first-to-deliver-a-pi3k-inhibitor-for-head-and-neck-squamous-cell-carcinoma 2024-11-11T09:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/7a6e4f53f23c1cba/cancer-killing-virus-shows-promise-against-aggressive-brain-tumors 2024-11-11T09:19:42+00:00 weekly 0.7 https://trial.medpath.com/news/10d6ef88a15dd76c/transgene-reports-business-pipeline-and-financial-update-for-q3-2024-pharmiweb-com 2024-11-11T09:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/eab50a11bd1a7d01/research-suggests-no-need-for-yellow-fever-vaccine-booster-after-initial-dose 2024-11-11T09:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/8ae0a777684ee1f4/shandong-xinhua-pharma-secures-key-drug-approval-tipranks-com 2024-11-11T09:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/22db529158b3ef08/ocugen-provides-business-update-with-third-quarter-2024-financial-results-biospace 2024-11-11T09:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/32529f9d90e3cf86/trump-s-healthcare-agenda-raises-concerns-rfk-jr-s-potential-role-and-aca-s-future-in-focus 2024-11-11T09:11:05+00:00 weekly 0.7 https://trial.medpath.com/news/3eaef433d29baf35/neurizon-therapeutics-receives-positive-opinion-on-orphan-medicinal-product-menafn 2024-11-11T09:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/629bb4ecc30ca0d6/dizal-seeks-fda-approval-for-nsclc-treatment-sunvozertinib-pharmaceutical-technology 2024-11-11T09:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/07fd7a9e63173dbb/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T09:01:39+00:00 weekly 0.7 https://trial.medpath.com/news/920e8585688ec5c8/australia-and-uk-team-up-to-fund-clinical-trials-research-professional-news 2024-11-11T08:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/728ba87bce2f2432/sweden-cereno-scientific-secures-financial-runway-into-2026-investors-in-healthcare 2024-11-11T08:55:20+00:00 weekly 0.7 https://trial.medpath.com/news/92573c548e206906/imugene-doses-first-patient-in-hard-to-treat-cancer-drug-trial-the-west-australian 2024-11-11T08:36:44+00:00 weekly 0.7 https://trial.medpath.com/news/70a6712dbe26eb56/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T08:36:31+00:00 weekly 0.7 https://trial.medpath.com/news/439c99f9b6e9c636/syncona-s-autolus-gets-fda-approval-for-leukaemia-treatment-sharecast-com 2024-11-11T08:23:24+00:00 weekly 0.7 https://trial.medpath.com/news/c0ffe68a8ecd2906/fda-to-finally-ban-controversial-ingredient-in-popular-decongestants-sciencealert 2024-11-11T08:20:43+00:00 weekly 0.7 https://trial.medpath.com/news/e750d4e0b9a16c83/investment-surges-hurdles-and-emerging-innovations-in-neuroscience-yahoo 2024-11-11T08:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/fa0c715dbaecc8c6/neurizon-therapeutics-receives-positive-opinion-on-orphan-medicinal-product-pr-newswire 2024-11-11T08:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/6faa512cfe093b80/autolus-receives-fda-approval-for-aucatzyl-in-adults-with-relapsed-refractory-b-all 2024-11-11T08:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/6820fc1059b3737c/enterobiotix-announces-positive-ph1b-clinical-results-of-ebx-102-in-liver-cirrhosis 2024-11-11T08:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/cb369364aa1f9e53/syncona-autolus-receives-fda-approval-for-aucatzyl-in-adults-with-relapsed-refractory-b-all 2024-11-11T07:55:36+00:00 weekly 0.7 https://trial.medpath.com/news/8035e896d8cfeedf/luye-pharma-gains-approval-for-innovative-antidepressant-trials-markets-insider 2024-11-11T07:55:36+00:00 weekly 0.7 https://trial.medpath.com/news/cee8eb07b082b903/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/b52227cf96422486/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-11T07:44:20+00:00 weekly 0.7 https://trial.medpath.com/news/772f26e8436ce6d6/largest-t-cell-clinical-trial-in-solid-tumors-heralds-new-era-in-precision-immunotherapy 2024-11-11T07:41:29+00:00 weekly 0.7 https://trial.medpath.com/news/03bba1d54f6cb72e/gamma-delta-t-cells-emerge-as-promising-alternative-to-car-t-for-solid-tumors-and-autoimmune-diseases 2024-11-11T07:41:26+00:00 weekly 0.7 https://trial.medpath.com/news/ea30119a1c494287/alembic-pharma-gets-usfda-approval-hypertension-drug-india-infoline 2024-11-11T07:38:49+00:00 weekly 0.7 https://trial.medpath.com/news/ab570facd31a0879/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:20:56+00:00 weekly 0.7 https://trial.medpath.com/news/ca31764622b58d46/oncoinvent-announces-promising-interim-results-for-radspherin-r-as-a-potential-treatment 2024-11-11T07:20:41+00:00 weekly 0.7 https://trial.medpath.com/news/722cd8907536c7a5/angle-plc-announces-parsortix-enriched-ctc-ctdna-in-nsclc-patients-stock-titan 2024-11-11T07:17:37+00:00 weekly 0.7 https://trial.medpath.com/news/87a83a5cd779f71f/syncona-s-autolus-gains-fda-approval-for-leukemia-therapy-tipranks-com 2024-11-11T07:14:05+00:00 weekly 0.7 https://trial.medpath.com/news/7832e73224104327/hemogenyx-pharmaceuticals-secures-funding-for-clinical-trials-tipranks-com 2024-11-11T07:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/cc147da008ffa726/cereno-scientific-secures-sek-250-million-in-debt-financing-marketscreener 2024-11-11T07:08:53+00:00 weekly 0.7 https://trial.medpath.com/news/34754b4378ed27bf/autolus-receives-us-fda-approval-company-announcement-investegate 2024-11-11T07:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/b94e5763f20246fc/investment-surges-hurdles-and-emerging-innovations-in-neuroscience 2024-11-11T07:06:01+00:00 weekly 0.7 https://trial.medpath.com/news/de152ef4c263ba8e/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/5d51182f61afef9e/biomarker-testing-revolutionizes-treatment-approaches-in-diffuse-large-b-cell-lymphoma 2024-11-11T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5733cb838ce3906e/corvus-pharmaceuticals-announces-new-data-highlighting-potential-of-ciforadenant-biospace 2024-11-11T06:50:03+00:00 weekly 0.7 https://trial.medpath.com/news/8607a55b039fd019/relief-therapeutics-eb-treatment-shows-78-wound-closure-rate-in-breakthrough-trial 2024-11-11T06:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/91197f9cbd2b0d1f/curasight-announces-brain-cancer-as-first-indication-for-utreat-r-first-patient-to-be-dosed 2024-11-11T06:34:54+00:00 weekly 0.7 https://trial.medpath.com/news/b27c99a1e2617139/japan-recommends-approval-of-brukinza-balversa-citeline 2024-11-11T06:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/92effc00d4f1dd17/biotech-industry-adapts-to-evolving-challenges-ai-and-innovation-key-to-clinical-trial-success 2024-11-11T06:29:13+00:00 weekly 0.7 https://trial.medpath.com/news/4f2f08a63b46edd4/comparative-cardiovascular-and-renal-outcomes-of-liraglutide-versus-dulaglutide-in-asian 2024-11-11T06:28:30+00:00 weekly 0.7 https://trial.medpath.com/news/7e32d1bc6e30a31f/major-t-cell-trial-in-solid-tumors-marks-new-era-mirage-news 2024-11-11T06:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/a0713cec31f4ca72/alembic-pharma-gets-usfda-nod-for-hypertension-treatment-drug-cnbc-tv18 2024-11-11T05:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/5f6fbe943211bb09/johnson-johnson-seeks-us-eu-approvals-for-darzalex-faspro-darzalex-as-pharmabiz-com 2024-11-11T05:31:18+00:00 weekly 0.7 https://trial.medpath.com/news/13fcfd428ec4c489/after-decades-of-failure-first-disease-modifying-huntington-s-treatment-on-the-horizon 2024-11-11T05:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/5e53cea48f73f67d/5-huntington-s-therapies-to-watch-biospace 2024-11-11T05:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/db5d30d5738a17ec/pe-cgs-network-advances-patient-partnered-cancer-research-despite-implementation-challenges 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d783381438dea264/genetic-study-reveals-strong-links-between-hidradenitis-suppurativa-and-cardiometabolic-diseases 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2aa10788cac4e235/new-heart-valve-device-at-musc-offers-safer-treatment-for-tricuspid-regurgitation 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3c4166648d188961/clarity-and-nucleus-radiopharma-scale-up-manufacturing-for-cancer-treatment 2024-11-11T04:50:53+00:00 weekly 0.7 https://trial.medpath.com/news/bbd5ced4d41ae367/lupin-receives-tentative-u-s-fda-approval-for-raltegravir-tablets-express-pharma 2024-11-11T04:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/937861a088bb5b6f/parkinson-s-disease-clinical-research-in-7mm-focuses-on-disease-modifying-agents-says-globaldata 2024-11-11T04:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/4987bb09e63d7903/quick-listen-scrip-s-five-must-know-things-citeline 2024-11-11T04:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/db47d0f9f80b4cf3/hope-for-kenyans-as-kemri-recommends-new-hiv-prevention-drugs-tv47-digital 2024-11-11T04:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/0d4753f45ea73aab/imugene-expands-car-t-cell-and-oncolytic-virotherapy-trials-in-australia-and-the-us 2024-11-11T04:23:42+00:00 weekly 0.7 https://trial.medpath.com/news/34f1c506c7f65e21/while-the-orphan-battles-wage-jazz-takes-a-loss-food-and-drugs-law-mondaq 2024-11-11T03:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/4f30b537959af88c/daiichi-sankyo-astrazeneca-s-enhertu-receives-2024-prix-galien-usa-award-for-best 2024-11-11T03:29:34+00:00 weekly 0.7 https://trial.medpath.com/news/f6843e49567de649/ema-accepts-marketing-authorization-application-for-alvotech-s-avt05-golimumab 2024-11-11T03:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/5d98b8e1d91c0982/alphamab-oncology-presents-the-latest-clinical-data-of-anti-her2-bispecific-adc 2024-11-11T03:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/c3be34611cb7ff5f/unicycive-therapeutics-announces-u-s-fda-acceptance-of-the-new-drug-application-nda-for-oxylanthanum-carbonate-olc-for-the-treatment-of-hyperphosphatemia-in-patients-with-chronic-kidney-disease-on-dialysis 2024-11-11T03:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/7cff93615e8602ee/recce-pharmaceuticals-advances-phase-3-trial-in-indonesia-markets-insider 2024-11-11T03:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/942479c56e5cd08d/late-breaking-abstract-alphamab-oncology-presented-the-latest-clinical-data-of-anti 2024-11-11T02:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/057be18b2ad161f2/nipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-adults-living-with-moderate-to-severe-sjogrens-disease 2024-11-11T02:11:39+00:00 weekly 0.7 https://trial.medpath.com/news/c86e8cbe1e0c773f/abbvie-provides-update-on-phase-2-results-for-emraclidine-in-schizophrenia 2024-11-11T02:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/32c008a1e67156e3/sino-biopharm-s-garsorasib-gains-approval-in-china-markets-insider 2024-11-11T02:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/653cfa4ed5f36c48/ultragenyx-presents-positive-update-on-gtx-102-angelman-syndrome-program 2024-11-11T01:38:19+00:00 weekly 0.7 https://trial.medpath.com/news/002401a8ad35259c/recce-pharmaceuticals-garners-ethics-approval-for-anti-infective-phase-3-clinical-trial-in-indonesia 2024-11-11T01:20:59+00:00 weekly 0.7 https://trial.medpath.com/news/eeab0072806da32d/australia-s-clarity-pharma-jumps-on-deal-with-us-co-tradingview 2024-11-11T01:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/7e0bf1926aa17b2f/could-everyday-plastics-be-impacting-your-fertility-newcastle-hmri 2024-11-11T00:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/7c153363d04ef459/ai-vs-humans-are-ai-chatbots-ready-for-real-mental-health-conversations-hmri 2024-11-11T00:29:53+00:00 weekly 0.7 https://trial.medpath.com/news/a7361099bf8bac99/ai-algorithm-achieves-80-precision-in-detecting-long-covid-through-electronic-health-records 2024-11-11T00:15:39+00:00 weekly 0.7 https://trial.medpath.com/news/3ec74bead912b9b9/mayo-clinic-is-working-on-breast-cancer-vaccines-firstcoastnews-com 2024-11-11T00:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/c68bbafa08c2c9d2/new-study-shows-effectiveness-of-nanoparticles-in-diagnosing-treating-plaque-in-arteries 2024-11-11T00:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/64ad3fd7947a5a86/oculis-holding-promising-pipeline-and-market-potential-support-buy-rating 2024-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/79fb2fefc30894a5/pharma-biotech-stocks-on-the-move-in-october-claire-aitchison-livewire-markets 2024-11-10T23:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/a27883744f854df6/recce-pharmaceuticals-advances-phase-3-trial-in-indonesia-tipranks-com 2024-11-10T23:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/5ceafd0a6fd91514/naspghan-2024-pedfic-data-highlight-safety-of-odevixibat-in-pediatric-patients-with-pfic 2024-11-10T23:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/59cf286f65b7ea3b/participants-needed-for-clinical-trials-for-norovirus-nevada-appeal 2024-11-10T23:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/fedecdf51733a98b/digital-health-funding-roundup-aignostics-secures-34m-series-b-for-ai-powered-pathology-platform 2024-11-10T23:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/4512732ea75c4c27/world-first-cure-for-lethal-skin-disease-achieved-in-landmark-study-wehi 2024-11-10T22:56:13+00:00 weekly 0.7 https://trial.medpath.com/news/1b86741330b003b6/new-study-modelling-progressive-ms-in-the-lab-reveals-how-cholesterol-can-damage-nerves 2024-11-10T22:50:42+00:00 weekly 0.7 https://trial.medpath.com/news/956a6bd04bb33eaa/roflumilast-cream-0-15-addresses-unmet-needs-of-adults-children-with-atopic-dermatitis 2024-11-10T21:42:15+00:00 weekly 0.7 https://trial.medpath.com/news/92788221c87d5715/cullinan-therapeutics-advances-novel-cd19-t-cell-engager-for-autoimmune-disease-treatment 2024-11-10T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3a38e744d7913b54/fda-wants-to-pull-decongestant-found-in-many-cold-allergy-medicines-fox-26-houston 2024-11-10T19:26:10+00:00 weekly 0.7